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ABSTRACT

SHORT SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-CHLORO-7-BENZOYL 2,3DIHYDROBENZO[b]FURAN -3-CARBOXYLIC ACID(BRL-37959) AND ITS ANALOGS.

by

Shamsul Arefin Ahmed

The University of Wisconsin-Milwaukee, 2017
Under the Supervision of Professor M. Mahmun Hossain

The synthesis of BRL-37959 has previously been reported. As an NSAID, the compound
was tested for and found that it had very low gastric irritancy. Commercially available
NSAIDs are non-selective COX inhibitors that enhance the risk of gastric, duodenal
mucosal injury or erosions and ulcer problems as well as lead to nephrotoxicity. The
COX-2 selective inhibitor Celecoxib (Celebrex) increases the risk of serious
cardiovascular (CV) thrombotic events, myocardial infarction and stroke as well as
increased nephrotoxicity. COX inhibitors are active against inflammation, pain, fever and
different types of cancers. Considering the enormous potential benefits and side effects
of non-selective COX inhibitors and selective COX-2 inhibitor. Our research goal was to
ii

find a COX inhibitor that binds with both COX-1 and COX-2 in such a ratio that it would
be a safer drug. Another aim was to develop a synthesis method of the target inhibitor
that will be simple, cost-effective and ensure high yield. Benzofuran is an important
building block of BRL- 37959. In Dr. Hossain's lab, Matt Dudley had developed a novel,
unprecedented, one pot procedure to synthesize various benzofuran derivatives. We
have followed the efficient, large scale potential, high yield and simple process to
synthesize benzofuran. Based on the synthesis of benzofuran, we have developed a short
and more cost-effective procedure for the synthesis of BRL-37959. The older method was
tedious and resulted in very low yields (≤ 5%). This new method is simple and uses
inexpensive starting materials, as well as giving high overall yields (62%). In enzyme
screening, we found that BRL-37959 selectively binds with COX-1. We followed our
improved method and successfully made some analogs with higher yield.
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Introduction
Benzofuran, an important class of heterocyclic compound is present in as a core moiety
in different natural products and pharmaceuticals as well as polymers. Many derivatives
of benzofuran of natural and synthetic sources have biological properties such as antiinflammatory, antimicrobial, antifungal, antihyperglycemic, analgesic, antiparasitic, and
antitumor activities.1-7 Several Non-steroidal anti-inflammation drugs (NSAIDs) possess
the benzofuran scaffold such as morphine, codeine, oxycodone, BRL-37959, naltrexone
and naloxone (Figure-1).

1.2. NSAIDs
NSAIDs are used mostly in the treatment of inflammation, pain, and edema, as well as of
osteoarthritis, rheumatoid arthritis, and musculoskeletal disorders. Because of selectivity
to cyclooxygenase (COX) enzymes, all available NSAIDs are classified into two
categories. (Table-1)

1.2.1 NASIDs and their Function
NSAIDs block the active sites of both COX1 and COX2 and thus prevents prostaglandin
formation. Almost all NSAIDs are non-selective and bind to both enzymes, but relieve
patients from inflammation, pain, and fever as well as create gastric irritancy, ulcers and

1

Morphine

Codeine

BRL-37959

Oxycodone

Naltrexone,

Naloxone

Figure 1- Different types of NSAIDs and Opioids.
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Table 1 - Different Nonsteroidal anti-inflammatory drugs
Non-selective (COX-1 and 2)
(traditional, conventional)
Aspirin

Selective (COX-2)
Celebrex
(Celecoxib)
Rofecoxib
Valdecoxib
Parecoxib
Celecoxib
Etoricoxib
Lumiracoxib

Acetaminophen
Indomethacin (Indocin)
Ibuprofen (Advil, Motrin)
Naproxen (Aleve, Naprosyn)
Sulindac (Clinoril)
Diclofenac (Voltaren,
Cataflam)
Piroxicam (Feldene)
β- Piroxicam (Cycladol)
Meloxicam (Movatec)

Selectives (COX-2)
COXIBs
Rofecoxib
Valdecoxib
Parecoxib

Ketoprofen (Profenid)

renal failure over long term use. The COX, non-selective NSAIDs inhibit the secretion
of prostaglandins in the gastrointestinal mucosa and produce gastroduodenitis,
gastric ulcers, and digestive bleeding. Since non-selective NSAIDs block COX-1 in
the gastrointestinal mucosa and they consequently inhibit the production of
prostacyclin, PGE2, and PGD2 in the stomach8-13 but cause adverse side effects.
These effects prostaglandins act as cytoprotective agents of the gastrointestinal
mucosa; they inhibit the acid secretion by the stomach, increase the blood flow and
the production of the protective mucus. However, COX1 enzymes releases
prostaglandins, prostacyclin, PGE2 and PGD2 in kidneys, dilate the vasculature,
reduce the renal vascular resistance and boost the organ perfusion(Figure-2).14
These effects lead to the redistribution of the blood flow from the renal cortex to the
nephrons in the intramedullary region.15,16The inhibition of these mechanisms tends
to decrease the total renal perfusion and rearrange the blood flow to the cortex; a
3

progression that ends in severe renal vasoconstriction, medullary ischemia and,
under certain conditions, acute kidney failure.COX1 enzyme releases thromboxane
that aggregates platelet and COX2 enzyme synthesizes prostaglandins that act as a
vasodilators. This prostaglandin keeps blood vessel free from clogging. There is a
dynamic balance between the platelet aggregation and vasodilation. The selective
COX-2 inhibition in the heart creates a tendency to thrombosis, due to the shift in the
pro-thrombotic/anti-thrombotic balance on the endothelial surface and damage of the
protecting effect of the up- regulation of COX-2 in cardiac ischemia and myocardial
infarction18-20 (Figure- 3).

↓ Renal PG
Vasoconstriction

↓ TXA2 synthesis

↓ Glomerular BF

↓ Platelet activation

↓ Glomerular filtration

COX-1 inhibition
(predominant)

↓ Gastric acid secretion

↓ PGI2 e PGE2 in

Mucosal dysfunction/lesion

the GI tract

GI-erosions, ulcerations and
hemorrhage

Figure 2 - Representation of the effects related to COX-1 inhibition. COX - cyclooxygenase; PG prostaglandin; TX - thromboxane; GI - gastrointestinal.
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↑ TXA

↓ Renal PG

↓ PGI

Platelet activation

↓ RA vasodilation

Vasoconstriction

↓ Vasopressin antagonism

↑ Risk of

↓ GBF

COX-2 selective
inhibition

Loss of protective effect
of the up-regulation of

Sodium and water
retention Edema

COX-2 → Ischemia, AMI

KF and HF worsening

Figure 3 - Schematic representation of the effects related to COX-2 inhibition. COX - cyclooxygenase; PG prostaglandin; TX - thromboxane; GI - gastrointestinal; RA - renal arteriole; GBF - glomerular blood flow;
AMI - acute myocardial infarction; HF - heart failure; KF - kidney failure

Celebrex, the only COX2 selective inhibitor is available on the market, because of
cardiovascular problems, the FDA applied restriction on its use. Moreover, at present,
there are no non-opioids safe drugs for inflammation and pain.
Opioids are a group of medications that include the illegal drug heroin, synthetic opioids
such as fentanyl, and prescription pain relief drugs such as oxycodone (OxyContin®),
hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are
chemically associated and act on opioid receptors on nerve cells in the body and brain.
Chronic pain affects about 100 million people in the USA, or one-third of the U.S.
population, and it is the prime reason of disability. While many treatments are
recommended for pain, the number of prescription opioids has increased immensely in
recent years.
5

1.2.2. Global market of NSAIDs

Up-to-date treatments for pain principally include non-steroidal anti-inflammatory drugs
("NSAIDs") for mild to moderate pain and opioids for moderate to severe and chronic
pain. The opioids are disreputable related to tolerance and dependence, whereas safety
issues with Cox-2 inhibitors, a significant class of NSAIDs, have limited their use. In 2014,
the global pain management market for pharmaceuticals and medical devices was worth
$36.6 billion21 and for NSAID drugs segment was $11.4 billion in 201422. An aging world
population has prompted the growth in this sector, in addition to an increased incidence
of obesity and osteoarthritis, as well as changing views towards pain management. Aged
people are more susceptible to illness such as arthritis, joint or bone pain, epilepsy,
depression, nerve damage, diabetic neuropathy, and different types of injuries due to low
resistance levels. The global population of geriatrics (people aged 65 years or more) is
expected to rise to 2 billion by 2050, accounting for nearly 22% of the projected global
population. This demographic will lead to a substantial increase in the overall world
demand for different pain management medications, thereby driving the global pain
management therapeutics market23. Allied Market Research has estimated that the antiinflammatory therapeutics market will reach $106.1bn, globally in 2020. In regard to
product types, the global pain management drugs market is presently dominated by
opioids and non-steroidal anti-inflammatory drugs (NSAIDs), whose total share was over
52% of the market's overall revenues in 2015. North America led the market, accounting
for over 56% of the overall market in the same year.
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1.2.3. Opioids market size and abuse

Opioids are used as anesthetics, cough suppressants, diarrhea suppressants and to
reduce surgical pain, injury or trauma, cancer pain, as well as pain intensifying from other
diseases. Opioids are primly used in cancer pain management and end-stage diseases
in which supportive care is required. The worldwide opioids market was approximately
US$ 339.24 billion in 2014.

By product, the morphine and codeine sections together accounted for around 62% of
the overall market in 2014. North America was the top market for opioids, and it had
approximately 65% of the revenue share in 2014, followed by Europe with around a 20%
share in 2014. Some factors such as increasing palliative care facilities, reformed
regulations for prescription of opioids, and increased attention of generic manufacturers
towards Abuse-Deterrent Formulation (ADF) have

driven

the growth of the opioid

market in North America and Europe. By 2021, the global opioids market revenue is
postulated to be about US$ 421.6 billion.

Prescription opioid pain relievers are usually safe if used for a short time, but because
they create elation in addition to pain relief, people abuse these (taken in a different way
or a larger quantity than prescribed, or taken without a doctor's prescription). Logical use
even as prescribed by a doctor can lead to dependence and, once misused, opioid pain
relievers can lead to overdose incidents and deaths.
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More than 90 people in the United States die in a day because of opioids overdose.25 The
misuse of and addiction to opioids together with prescription pain relievers, heroin, and
synthetic opioids such as fentanyl is an acute national crisis that influences public health
as well as social and economic welfare. The Centers for Disease Control and Prevention
estimates that the total "economic burden" of prescription opioid abuse only in the United
States is $78.5 billion a year, including the cost of healthcare, lost productivity, addiction
treatment, and involvement of the criminal justice.26

In 2015, more than 33,000 persons in the united states died in the aftermath of an opioid
overdose, including prescription opioids, heroin, and illicitly manufactured fentanyl, a
powerful synthetic opioid.25 Approximately 2 million people in the United States agonized
from substance use disorders related to prescription opioid pain relievers, and 591,000
suffered from a heroin use disorder (not mutually exclusive) in 2015.27 For more
information about the opioid crisis:


About 21 to 29 percent of chronic pain patients misuse prescribed opioids.28



Among 8 and 12 percent build up an opioid use disorder.29-31



4 to 6 percent who misuse prescription opioids switch to heroin.29-31



Roughly 80 percent of people who use heroin, first abused prescription opioids.29
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Figure 4 - National Overdose Deaths—Number of Deaths from All Drugs.

Figure 5 - National Overdose Deaths—Number of Deaths from Opioid Drugs.
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Figure 6- National Overdose Deaths—Number of Deaths from Prescription Opioid
Pain Relievers (excluding non-methadone synthetics).

Figure 7- National Overdose Deaths—Number of Deaths from Benzodiazepines.
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Figure 8- National Overdose Deaths—Number of Deaths from Benzodiazepines,
with and without opioids.
1.3 Background
In 1986, Boyle32 and her co-worker synthesized BRL-37959 (5) and found that the
compound was active as a Non-Steroidal Anti- Inflammatory Drug (NSAID). Zomepirac
(brand name Zomax), an equipotent drug as BRL-37959, was used as a reference
compound(Table-1). Zomax replaced morphine for relieving postoperative pain. It is not
addictive but was withdrawn from the market in 1983 because it caused anaphylaxis, a
severe allergic reaction, in patients.
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Figure 9-Structural analysis of BRL 37959

Since 1983, no reasonable non-opiate drug is available for postoperative pain. BRL
37959 may be used as an alternative NSAID, like VIOXX (Rofecoxib), which causes little
gastric irritation, but has been withdrawn from the market because it increases the risk of
heart attack.

Table-2: Biological data of racemic BRL-37959 vs Zomax.
Compound

Analgesia (ED50) PG Synthase (ID50)

Zomepirac(Zomax)

0.6
(0.4-1.0)

0.6

Racemic BRL-37959

0.8
(0.5-1.3)

0.25

Gastric
irritancy(ED50)
8
(4.2-15.4)

150
(87.2-258.0)

Note: ED50 = Effective dose in mg/kg with 95% confidence limits in parentheses.
ID50 = inhibitory dose of prostaglandin synthetase (PG) in mg/ml
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1.4 Aim of the Project:
Non-selective commercially available COX inhibitors enhance the risk of gastric and or
duodenal mucosal injury or erosions, ulcers and ulcer problems including bleeding as well
as lead to nephrotoxicity.18,19. The COX-2 selective inhibitor Celecoxib (Celebrex)
increases the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction
and stroke as well as increased nephrotoxicity.

It is well known that COX1 enzyme releases thromboxane that aggregate platelets and
COX2 enzyme synthesize prostaglandins that act as a vasodilator. This prostaglandin
keeps blood vessel free from clogging. There is a dynamic balance between the platelet
aggregation and vasodilation. Therefore, COX inhibitors are active against inflammation,
pain, and fever as well as different types of cancers. Considering the enormous potential
benefits and side effects of non-selective COX inhibitors and selective COX-2 inhibitors,
our research goal was to find out a COX inhibitor that binds with both COX1 and COX2
in such a ratio that it would be a safer drug. Also, another aim was to develop a synthesis
method of the target inhibitor that would be simple, cost efficient and ensure a high yield.

Boyle and her colleges found that BRL-37959 had less gastric irritancy than zomepirac.
But this drug is not available on the market, in search of its reason we have found that
the overall yield of Boyle's method is a meager (≤ 5%).
Benzofuran is an essential building block of BRL 37959. In Dr. Hossain's lab, Matt
Dudley33 had developed a novel, unprecedented, one pot procedure to synthesize various
benzofuran derivatives. We have followed this efficient, more economical, large scale
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potential, selective, high yield and simple process to synthesize benzofuran and designed
a synthetic route to synthesize BRL-37959 with higher yield.

1.5. Binding mode of NSAIDs with Cyclooxygenase (COX) enzymes

1.5.1. Cyclooxygenase (COX) enzymes and their function
Phospholipase(PLAs)

of

plasma

membranes

release

arachidonic

acid

and

cyclooxygenase enzymes convert this into prostaglandins. Prostaglandins are signaling
molecules that facilitate a different group of physiological actions throughout the body.
Various types of tissues specific prostaglandins such as PGD2, PGE2, PGI2, PGF2, TxA2
are formed. Prostanoids then exert their effects by signaling through separate G-protein
coupled receptors (GPCRs).34-35 Prostaglandin signaling is involved in a variety of
biological functions. For example, prostanoids play a significant role in the maintenance
of vascular homeostasis. Vascular endothelium-derived PGI2, a vasodilator, and an antithrombotic agent are thought to counterbalance the effects of TXA2, which induces
vasoconstriction and thrombosis.36-39 PGE2 and PGI2 are also important regulators of
kidney function and gastric cytoprotection.41-42Pathophysiological responses mediated by
prostanoid signaling include pain, fever, inflammation, and tumorigenesis37,43,45 and has
been in reference in.45-47 Phospholipase (PLAs) of plasma membranes releases
arachidonic acid, and cyclooxygenase enzymes convert it into prostaglandin PGF and
thromboxane A2 (TXA2), together termed as prostanoids. There are four principal
bioactive PGs generated in vivo: prostaglandin E2 (PGE2), prostacyclin (PGI2),
prostaglandin D2 (PGD2), and prostaglandin F2 (PGF2)
14

Prostaglandin E2

Prostaglandin E2 (PGE2) is generated in large amounts in the body and has a broad
range of biological functions such as regulation of immune responses, blood pressure,
gastrointestinal integrity, and fertility. PGE2 plays an important role in causing
inflammation, redness and pain. PGE2 contributes to the growth of arterial dilation and
enhanced microvascular permeability that increases blood flow to the inflamed tissue, as
well as leads to the common sign of inflammation: redness, swelling, and pain. Pain is
the result of the action of PGE2 on peripheral sensory neurons and on central sites within
the spinal cord and the brain.48
PGI2 and Inflammation

PGI2 regulates cardiovascular homeostasis. PGI2 is found in vascular cells, including
endothelial cells, VSMCs, and endothelial progenitor cells49-50 PGI2 is produced by the
consecutive action of COX and PGIS, a member of the cytochrome P450 superfamily that
positively transforms PGH2 to PGI2. PGIS localizes with COX in the endoplasmic
reticulum, plasma membrane, and nuclear membrane.41-52 PGIS is initially expressed in
endothelial cells, where it combines with COX-1,25 although the COX-2-dependent PGI2
generation by endothelial cells has been stated to be modified in vivo. This is done to
thrombin, shear stress, oxidized low-density lipoprotein, hypoxia, and inflammatory
cytokines, as well as upregulation of COX-253-54 which harmonizes it. PGI2 is an effective
vasodilator and an inhibitor of platelet aggregation, leukocyte adhesion, and VSMC
proliferatio.47 PGI2 is also antimitogenic and inhibits DNA synthesis in the VSMC.55 These
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actions of PGI2 are facilitated through specific IP receptors (Table). This receptor is
expressed in the kidney, liver, lung, platelets, heart, and aorta.56
Besides its cardiovascular effects, PGI2 is a vital mediator of the edema and pain that
accompany acute inflammation. PGI2 quickly forms following tissue injury or
inflammation, and it is present at high concentrations in inflammatory milieus 57 PGI2 is
the most abundant prostanoid in synovial fluid in human arthritic knee joints, as well as in
peritoneal cavity fluid from mice injected with irritants.58-59

PGD2 and Inflammation

PGD2 is produced in both the central nervous system and peripheral tissues and appears
to function in both an inflammatory and homeostatic capacity.60 In the brain, PGD2
regulates sleep and other central nervous system activities, including pain perception.
62

51-

In peripheral tissues, PGD2 is synthesized mainly by mast cells but also by other

leukocytes, such as DCs and Th2 cells.63-64Two genetically distinctive PGD2-producing
enzymes have been recognized, including hematopoietic- and lipocalin-type PGD
synthases (H-PGDS and L-PGDS, respectively). H-PGDS is usually confined to the
cytosol of immune and inflammatory cells, while L-PGDS is more reserved to tissuebased expression.64-65

PGF2α and Inflammation

PGF2, originated mostly from COX-1 in the female reproductive system, plays a
significant role in ovulation, luteolysis, contraction of the uterine smooth muscle, and
16

initiation of parturition.66-67 Recent studies have revealed that PGF2 also plays a major
role in renal function68, contraction of arteries69, myocardial dysfunction,70-71brain injury,72
and pain.73Administration of PGF2 produces acute inflammation, and NSAIDs inhibit
PGF2 biosynthesis both in vitro and in vivo.74 Elevated biosynthesis of PGF2 has been
found in patients suffering from RA, psoriatic arthritis, reactive arthritis, and osteoarthritis.
Cardiovascular risk factors, such as diabetes, obesity, smoking, and thickening of the
intima-media ratio in the carotid artery, have been randomly related with elevations in
PGF2 metabolites, together with IL-6 and acute phase proteins in body fluids.76—77 The
sprouting role of PGF2α in acute and chronic inflammation opens up opportunities for the
design of new anti-inflammatory drugs.

Thromboxane and Inflammation

Thromboxane A2 (TXA2) is a type of thromboxane, synthesized from PGH2 via
thromboxane synthase, and it is non-enzymatically degraded into biologically inactive
TXB2. TXA2 is principally derived from platelet COX-1, but it can also be made by other
cell types, including macrophage COX-2.78-79 TXA2 activity is mainly mediated through
the TP, which couples with GQ, G12/13, and multiple small G proteins, which in turn
control several effectors, including phospholipase C, small G protein Rho, and adenylyl
cyclase (Table-3).92 TP and TP,2 spliced isoforms of TP in humans, communicate with
different G proteins and undergo hetero-dimerization, which results in alteration to
intracellular traffic and receptor protein conformations. Only the TP protein is expressed
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Figure 10- Biosynthesis of prostanoids.
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in mice. TP activation arbitrates several physiological and pathophysiological responses,
with platelet adhesion and aggregation, smooth muscle contraction and pro-function is
controlled by several factors, such as oligomerization, desensitization, internalization,
glycosylation, and crosstalk with receptor tyrosine kinases94 TP and TP, spliced iso-forms
of TP in humans, communicate with different G proteins and undergo hetero-dimerization,
which results in alteration to intracellular traffic and receptor protein conformations. While
TXA2 is the favored physiological ligand of the TP receptor, PGH2, in specific, can also
activate this receptor94.The cutting of TP decreases vascular proliferation and platelet
activation in response to vascular injury, which delays atherogenesis, and prevents
angiotensin II– and L-NAME induced hypertension and the associated cardiac
hypertrophy.95-96

1.5.2. COX reaction

The transformation of AA to the parental prostaglandin, PGH2, takes place at two
specifically unique but functionally coupled active sites within the COX enzymes.
The bis-deoxygenation of AA occurs in the L-shaped cavity of the COX active site, leading
to the formation of the hydroperoxy endoperoxide, prostaglandin G2 (PGG2).85PGG2
then moves out of the COX site to the peroxidase (POX) active site, where it rapidly is
reduced by accepting two-electrons to form the hydroxy endoperoxide, PGH243.
Hydroperoxides except PGG2 can be reduced in the POX active site, and
commencement of the COX reaction is dependent upon a two-electron oxidation of the
heme moiety at the POX site. The requirement for heme oxidation at the POX active site
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to initiate COX catalysis is best described by a branched-chain mechanism, as shown in
Figure 11. The two-electron oxidation of heme takes place in conjunction with the twoelectron reduction of a hydroperoxide substrate, and results in the formation of a ferryloxo protoporphyrin radical cation ((PPIX•) +Fe4+O) designated Compound I.86-87 In the
presence of a reducing co-substrate, two subsequent one-electron reductions restore the
heme moiety to its original state.88-89Otherwise, Compound I can abstract a hydrogen
from Tyr-385 in the COX active site, which results in the formation of a tyrosyl radical,
thus commencing the oxygenase reaction.

1.5.3. Structure of COX enzymes
1.5.3.1. General COX structure
In 1994, the first three-dimensional structure of COX-1 was made, and two years later the
crystal structure of COX-2 was obtained.89,90 Subsequent cleavage of the signal
sequence, mature COX-1 contains amino acid residues 25-600, with residues 33-586
displaying clear electron density in crystallographic analysis89. Also, residues 33-583
were determined in the first crystal structure of COX-2; 35 amino acids at the C-terminus
could not be traced.90 A 14-amino acid elimination at the N-terminus of COX-2 results in
the numbers of most COX-2 amino acids to be 14 units lower than those of COX-1, but
by convention, the amino acids of both isoforms are referred to by the numbering of the
initial COX-1 translation product. Comparison of the crystal structures of COX-1 and
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Compound

Figure 11- Branched chain mechanism for COX catalysis. In the POX, active site, the
heme moiety, (PPIX)Fe3+, undergoes a two-electron oxidation to form Compound
I, (PPIX•) Fe4+O, whereas the hydroperoxide substrate (ROOH) undergoes a twoelectron reduction. The enzyme can return to its original state by two subsequent
one- electron reductions or the radical can be transferred to a tyrosine residue in
the COX active site. While AA is bound within the COX active site, the newly formed
tyrosyl radical can abstract the 13-pro-(S) hydrogen from the fatty acid substrate.
AA undergoes several radical rearrangements in addition to two oxygenation
reactions to provide the development of the hydroperoxy endoperoxide, PGG2.
The radical is then shifted back to the tyrosine residue to allow the initiation of
subsequent catalytic cycles.
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discloses that the two isoforms have virtually superimposable structures with each. COX
monomer consists of three domains: an epidermal growth factor (EGF)-like domain, a
membrane binding domain, and a large globular catalytic domain, which holds the
cyclooxygenase (COX) and peroxidase (POX) active sites.89-91 The COX enzymes are
found as homodimers with an extensive dimer interface created by the EGF-like and
catalytic domains.92
Table 3: Summary of the structure, distribution and regulation of COX-1 and COX-2

cDNA
mRNA
Protein

Differences
Regulation

Tissue
Expression

COX1
Chromosome 9; 22kB
2.8kB
72kDa;599 amino acids

COX2
Chromosome 1; 8.3kB
4.5kB
72kDa;604 amino acids

Amino acids: 90% between species for both isoforms; similar
Vmax and Km values for arachidonic acid
Glucocorticoids inhibit expression of COX-2, not COX-1; the active
site of COX-2 is larger than that of COX-1
Predominantly constitutive.
Predominantly inducible
Increased 2- to 4-fold by
(10- to 20-fold)
inﬂammatory stimuli
Constitutive in certain tissues
Most tissues, but particularly Induced by inﬂammatory
platelets, stomach, kidney
stimuli and mitogens in
macrophages/ monocytes,
synoviocyes, chondrocytes,
ﬁbroblasts, endothelial cells.
Induced by hormones in the
ovaries and foetal membranes.
Constitutive expression in the
CNS, kidney, testes, tracheal
epithelial cells.

22

Domain construction
COX, a monotopic membrane protein that binds with phospholipid bilayer of the plasma
membrane as if it was a basic membrane protein.

The membrane-binding domain (residues 73-116) consists of four short amphipathic αhelices (A-D). The helices are placed approximately orthogonal to one another forming a
hydrophobic surface model for introduction into a single face of the membrane bilayer.
The helices of the membrane binding domain are also surrounded by a somewhat large
open area that has been termed the "lobby," as it is assumed that substrates and
inhibitors must travel through this zone to enter the active site located within the catalytic
domain.
The catalytic domain is physically homologous to mammalian myeloperoxidase,
indicating that the COX enzymes evolved from soluble heme-dependent peroxidases93.
This main domain of the COX monomer largely consists of a α-helical secondary
structure. The POX active site is located in a solvent-accessible trench at the top of the
catalytic domain while the COX active site lies at the vertex of a large, L- shaped
hydrophobic channel that ranges from the membrane-binding domain into the catalytic
domain. Inside the COX channel, the catalytic and membrane binding domains are
separated by a compression formed by three residues: Arg-120, Tyr-355, and Glu-524.
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The EGF-like domain is composed of a short sequence of amino acids at the N- terminus
(residues 34-72) of the protein, and its particular function remains unknown. However, it
has recommended that this domain may start and retain interactions necessary for the
insertion of COX into the membrane bilayer93.

POX active site:
The peroxidase active site (shown in Fig-12) is the position of heme binding where
His-388 serves as the proximal heme ligand. Gln-203 and His-207 are located on
the distal side of the heme, approximately 5 Å from the heme iron, but do not
coordinate the metal88. It is assumed that these residues play a key role in the twoelectron reduction of the hydroperoxide substrate.45 Mutation of His-388, Gln203, or His-207 results in a dramatic reduction in peroxidase activity.44,94 Recent
studies confirm that, while the kcat/Km for peroxidase activity of G203V oCOX-1
is 17% that of WT enzyme, the mutant enzyme holds full COX activity and has a
specific activity corresponding to that of WT proposing that this Glu-203 is not
needed for the initiation of COX catalysis.95
In contrary to the majority of peroxidases, the POX active site of COX enzymes is
exposed to solvent and can, therefore, hold large alkyl peroxide substrates. The
opening of the POX active site also permits for relatively easy dissociation of small
ligands, including heme, in and out of the active site cavity. Due to the nature of
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POX active site and the reactivity of the heme moiety, crystallization of substrates
or products attached to the peroxidase active site has been difficult. Lately, the
2.0 Å crystal structure of oCOX-1 in complex with an analog of the non-steroidal
anti- inflammatory drug (NSAID) flurbiprofen presented the first view of a ligand
bound to the POX active site (PDB ID: 1Q4G).96 A detailed explanation of NSAIDs
as COX inhibitors is provided below. Though, in this specific structure, a glycerol
molecule, used as a cryoprotectant, lies between Gln-203 and His-207 with the 1hydroxyl group located roughly above the heme iron (Figure 12)96. The 3-hydroxyl
group forms hydrogen bonding interactions with a water molecule coordinated to
His-20794. The position of this glycerol molecule is likely to mimic the binding
conformation of the peroxide moiety of alkyl hydroperoxide substrates. This
structure was used as the basis for docking and molecular dynamics studies for
predicting the productive binding mode of the hydroperoxy endoperoxide
intermediate, PGG2, within the POX active site97.
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His-207
Gln-203

His-388

Tyr-385

Figure 12- Glycerol molecule bound within the POX active site of COX-1. Heme (red stick
structure) is shown bound in the POX active site in addition to a glycerol molecule (blue and red)
shown in ball-and-stick mode. Key residues for peroxidase activity are shown in turquoise. The
catalytic tyrosine is shown in orange. PDB ID: 1Q4G.

1.6 COX active site
The COX active site channel ranges 25 Å from the membrane binding domain to the
interior of the catalytic domain; the catalytic center is placed on the upper half of the
channel from Arg-120 to Tyr-385. Although the COX-1 and COX-2 active sites are
somewhat similar, the COX-2 active site is about 20-30% larger than that of COX-1(Figure
13). The size variation is rather assigned to a single amino acid change (Ile-523 in COX1, Val in COX-2) that limits the gateway to a pocket of the main active site channel

99.

Substitution of secondary shell residues, Ile-434 and His-513, in COX-1 for Val-434 and
Arg-513 in COX-2 also makes the change in active site size.
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Figure 13- Solvent accessible surfaces in the cyclooxygenase active site of COX-1 and COX-2. The
catalytic domains of the COX proteins are shown as red in a ribbon diagram with the membrane binding
domains (predominantly helix D) shown in green. Residues lining the COX active site of both proteins are
shown in white with the solvent accessible surfaces in the active site designated as translucent light-blue.

It is confirmed from Crystal structures and molecular models of ovine COX-1 (oCOX-1)
and murine COX-2 (mCOX-2) that the carboxylic acid of the arachidonic acid ion-pairs to
the guanidinium group of Arg-120 and hydrogen bonds to Tyr-355. The aliphatic
backbone stirs up into the top of the cyclooxygenase active site from the hydrophobic
channel and then forms a distinct bend in the proximity to Tyr385 (Figure 14).100-104 In
these structures, because of van der Waals interactions, all most all the of contacts are
formed between the substrate and various protein residues in the active site. The ω-end
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Figure 14- Arachidonic acid bound in the active site of oCOX-1.32
The carboxylate of the substrate ion-pairs with Arg-120 and hydrogen
-bonds with Tyr-355 at the construction site, projects up the hydrophobic
channel, and makes an L-shaped bend around Tyr-385. The heme
prosthetic group is designated in red. Residues that are in contact with
arachidonic acid in the active site channel are shown in yellow.

of arachidonic acid links, up in a narrow channel at the top of the active site and is
surrounded by six aromatic amino acids. Mutation of Gly-533 at the top of this channel
caps off the channel and ends the oxygenation of arachidonic acid but not that of fatty
acids with shorter carbon chains104.
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1.7 Binding mode of NSAIDs to COX enzymes

1.7.1 Aspirin

Aspirin covalently alters both COX-1 and COX-2 over acetylation of Ser-530, it is 10-100
times more potent against COX-1 than against COX-2.105-107The cause for this variance
in inhibitor potency against the two cyclooxygenase isoforms is ambiguous. Without
acetylation, both COX enzymes predominantly create PGG2 and small amounts of
lipoxygenase-type products (hydroperoxy fatty acids), with either R or S stereochemistry
for the peroxide group at C-15.107-108 Acetylation of Ser-530 entirely stops arachidonate
catalysis and product formation in COX-1 but permits the synthesis of 15(R)hydroxyeicosatetranoic acid and 11(R)-hydroxyeicosatetranoic acid in COX-2. 103-104 This
disparity inhibition of the COX enzymes by aspirin is due to the larger volume of the
COX-2 active site produced by the Val-523 substitution at the mouth of the side pocket
109.Mutation of Val-523, Arg-513, and Val-434 in COX-2 to their COX-1 equivalents (Ile523,

His513,

Ile-434)

consequences

in

the

inhibition

of

15-

and

11(R)-

hydroxyeicosatetranoic acid formation subsequent treatment with aspirin.110
The crystal structure of COX-1 bound with 2-bromoacetoxybenzoic acid (an aspirin
analog) shows the integration of the bromoacetyl group at Ser-530 (Figure 15).111 Two
rotamers of the bromoacetyl group exist that blockade the active site channel to different
degrees; this may assist to clarify the different results of acetylation of COX-1 and COX2. In this structure, salicylic acid is also connected to the active site, which explains the
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Figure 15- Crystal structure of an aspirin analogue in the active site of
oCOX-1.57 The bromoacetyl group of the aspirin analogue 2-bromoacetoxybenzoic acid is shown covalently bound to Ser-530 in the COX active site
(red and orange linker). The product of the reaction, salicylic acid, is shown
in the active site with its carboxylate making hydrogen bonds with Arg-120
and Tyr-355 at the construction site. The bromoacetyl group of the inhibitor
and the salicylic acid product are shown in green and are colored by atom.
Key active site residues are shown in yellow.

selective delivery of the acetyl group to Ser-530. The salicylate carboxyl group ion-pairs
to Arg-120, which is positioned immediately below Ser-530. Mutation of Arg-120 to Gln or
Ala removes ion-pairing and hydrogen bonding interactions with the salicylate group and
significantly reduces aspirin acetylation of Ser-530.112 Another aspirin analog, oacetylsalicylhydroxamic acid113 also binds in the COX-1 active site channel, acetylates
Ser-530, and hydrogen-bonds with Arg-120 at the construction site. The acetyl group on
Ser-530 propels into the active site instantly below Tyr-385, shut down the top of the
channel and blocking the entrance of substrate to the catalytic tyrosyl radical. In the
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crystal structures of COX with aspirin analogs, a hydrogen bond is present between the
carbonyl oxygen of the acetyl adduct and the phenolic hydrogen of Tyr385.112,113 The
presence of Tyr-385 across the active site from Ser-530 plays a significant role of
acetylation.114 Mutation of Tyr-385 to Phe decreases aspirin acetylation of the serine
hydroxyl by 93%.112 The hydrogen-bonds between Tyr-385 and the acetyl group of
aspirin, which increases its reactivity by stabilizing the negative charge of the tetrahedral
intermediate of acetylation. This action of Tyr-385 is like the stimulation of substrate
acylation of serine proteases through the oxyanion hole in the active site.115Remarkably,
aspirin

acetylates

heme-reconstituted

enzyme

100-fold

more

rapidly

than

apoenzyme.116One probable clarification for this consequence is that the heme group
restricts protein conformational mobility and easiness enzyme-aspirin interactions. The
inhibition of COX enzymes by aspirin is also based on the oxidative state of the enzymes;
activation of COX with peroxides to form the Tyr-385 tyrosyl radical reduces acetylation
by aspirin.117The necessity of Tyr-385 and the heme prosthetic group for acetylation of
Ser-530 underlines the dynamic roles of the different parts of the cyclooxygenase active
site in the overall inhibition of its enzymatic activity by aspirin.
1.7.2. Flurbiprofen and Ibuprofen
X-ray crystallography of COX-inhibitor complexes and site focused mutagenesis studies
have assisted revealing the molecular basis for the time-dependent inhibition of some aryl
propionic and aryl acetic acid inhibitors. COX-1 crystal structures of competitive reversible
(ibuprofen and methyl flurbiprofen) and time-dependent (flurbiprofen and alclofenac (2(4-(allyloxy)-3-chlorophenyl) ethanoic acid)) inhibitors disclose the same binding
conformation of inhibitor in the active site. It indicates that the mechanism of time-
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dependent inhibition of COX thru NSAIDs does not include broad conformational changes
in the enzyme structure or the binding of the inhibitor to diverse, active sites. In the crystal
structure of COX-1 with flurbiprofen, the inhibitor binds to the cyclooxygenase active site
with the carboxylate of the inhibitor. Then it makes hydrogen-bond that links with Arg-120
and Tyr-355 at the constriction site (Figure 16A)118, The structurally alike, but kinetically
different, ibuprofen binds in an almost same style in the COX-1 active site, creating an
ion pair with Arg-120 and a hydrogen bond with Tyr-355 (Figure 17B).118These
crystallographic results recommend that the kinetic dissimilarities between competitive,
reversible and time-dependent, functionally irreversible inhibitors cannot entirely clarify
through the binding modes exhibited by these inhibitors.

Figure 16- Flurbiprofen and ibuprofen bound in the active site of ovine COX-1. Panel A shows a timedependent and functionally irreversible inhibitor, flurbiprofen (green), in the oCOX-1 active site with its
carboxylate coordinated to Arg-120 and Tyr-355 at the constriction site. Panel B shows a competitive
reversible inhibitor, ibuprofen (green), bound in a similar conformation. Key active site residues are shown
in yellow.
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1.7.3. Indomethacin
Crystal structure of indomethacin and COX-2 demonstrates that indomethacin binds
intensely within the cyclooxygenase active site (Figure 17A).119 The p-chlorobenzoyl
group progresses up into the active site channel, and the chlorine atom interacts with
Leu-384 at the top of the active site, whereas the benzoyl oxygen interacts with Ser-530.
The benzoyl group itself is stabilized by hydrophobic interactions with Leu-384, Tyr-385,
Phe-381, and Trp387. The carboxylate of indomethacin creates a salt bridge with Arg120 and builds additional interactions with Tyr-355 at the constriction site. The o-methoxy
group makes a large cavity provided by Ser-353, Tyr-355, and Val-523. The indole ring
interacts with Val-349, and the 2′-methyl group impels into a small hydrophobic pocket
formed by Val-349, Ala-527, Ser-530, and Leu-531 (Figure 17B).119 Mutagenesis of Val-

Figure 17 - Crystal structure of indomethacin in the active site of murine COX-2.60 Panel A
shows key active site residues important for inhibitor binding. Indomethacin is shown in
green and is colored by atom. Arg-120, Tyr-355, and Glu-524 at the constriction site are
shown in purple. Residues that constitute the small hydrophobic binding pocket (Val-349,
Leu-531, Ala-527, and Ser-530), as well as additional active site residues (Tyr-385), are
shown in yellow. Panel B is a space-filling model of the 2α-methyl group of indomethacin
(green) inserted into the hydrophobic binding pocket (yellow).104
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349 to alanine or leucine shows that introduction of the 2′-methyl group of indomethacin
into this small pocket is a crucial interaction responsible for the time-dependent inhibition
of COX enzymes by this inhibitor.120 A V349 A mutant enlarges the pocket size and raises
the potency of indomethacin compared to wild type mCOX-2 (0.08 vs. 0.25 µM), while a
V349L mutant cuts the pocket size and decreases the potency of the inhibitor (4.0 µM).
The KI of V349A for indomethacin association is almost 4-fold lower than wild-type
mCOX-2 with a slight increase in k2 (0.074 vs. 0.052 s-1), while V349L shows a 3-fold
increase in KI that accompanies a k2 of 0.074 s-1. Indomethacin reveals slow, timedependent, and functionally irreversible inhibition of both wild-type mCOX-2 and the
V349A mutant with no significant reverse rate constant (k-2) for the second inhibitory step
(eq 2). However, indomethacin exhibits reversible inhibition with the V349L mutant with a
measurable k-2 of 0.01 s-1. A2 ′-des-methyl analogue of indomethacin is a poor inhibitor
of mCOX-2 and the V349 mutants and is quickly competed off the enzymes by
arachidonic acid. 2-Des-methyl indomethacin does not inhibit COX-1 at all. Hence, a
critical factor of the time-dependent inhibition of COX by indomethacin is endorsed to the
binding of the 2′methyl group of the inhibitor into this small hydrophobic pocket.

1.7.4. Diclofenac

Diclofenac inhibition of COX-2 is not affected by mutation of Arg-120 to alanine or of Tyr355 to phenylalanine, with IC50 values for inhibition that is comparable to that of wild-type
mCOX-2 (wt, 77 nM; R120A, 257 nM; Y355F, 137 nM).60 However, a S530A COX-2
mutant is resistant to diclofenac inhibition (IC50 > 50 µM), proposing that Ser-530 is
important for inhibitor binding in the COX-2 active site. In support of this hypothesis, a
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S530M COX-2 mutant shows a greater than 240-fold growth in IC50 for diclofenac over
wild-type enzyme121.Also, diclofenac quenches the internal protein fluorescence of apo
COX-1 but does not quench the fluorescence of the aspirin-acetylated enzyme,
recommending that diclofenac must interact with Ser-530 in the COX active site for
binding and inhibition81.Most crystal structures of COX enzymes with carboxylic acidcontaining NSAIDs demonstrate the inhibitors located with their carboxylates coordinated
to Arg-120 and their aromatic functional groups stir up into the cyclooxygenase active
site. In contrary to diclofenac binds in the active site of COX-2 in a distinctive inverted
binding mode with its carboxylic acid moiety hydrogen-bonded to Ser-530 and Tyr-385
(Figure 18).104, 105 The inhibitor also builds great van der Waals interactions with several
hydrophobic residues inside the active site. For example, the phenyl acetic acid ring is
enclosed by the side chains of Tyr-385, Trp-387, Leu-384, and Leu-352. The
dichlorophenyl group makes van der Waals interaction with Val-349, Ala-527, Leu-531
(the indomethacin binding pocket), and Val-523. Unlike most other NSAIDs with
carboxylic acid moieties, neither Tyr-355 nor Arg120 creates contact with the inhibitor.
The unique binding mode of diclofenac is like the structure of the nonproductive complex
of arachidonic acid. COX-2 in which the substrate binds in an inverted conformation with
its carboxylate coordinated to Ser-530 and Tyr-385.41This positioning contrasts with most
structures resolved for fatty acid substrates attached to COX, including arachidonic acid,
where the carboxylate of the substrate forms hydrogen bonds or ion pairs with Tyr-355
and Arg-120. The novel, inverted binding of diclofenac and the nonproductive
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Figure 18- Crystal structure of diclofenac in the active site of murine
COX-2.60 Diclofenac binds in a novel, inverted orientation with its
carboxylate coordinated by Tyr-385 and Ser-530 at the top of the active
site. Diclofenac is shown in green and is colored by atom with each
chlorine atom colored in light-green. Arg-120, Tyr-355, and Glu-524
at the construction site are shown in purple. Additional key active site
residues are shown in yellow.104

conformation of arachidonic acid in COX-2 highlight the significance of Ser-530 and Tyr385 in ligand association and the chelation of negative charges in COX-2 and may
characterize a new binding mode demonstrated by some classes of NSAIDs.
1.7.5. Celecoxib analogue

The first crystal structure of human COX-2 (hCOX-2) displays that there is an overall
variance in the size and shape of the COX-2 active site compared to that of COX-130.
Almost 25% larger active site of COX-2 is due to the single Val-523 substitution (Ile in
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COX-1) in the active site and by the Arg-513 and Val-434 substitutions (His-513 and Ile434 in COX-1) in the secondary shell. The crystal structure of mouse COX-2 with the
celecoxib analog 4-(5-(4-bromophenyl)-3(trifluoromethyl)-1H-pyrazol-1-yl) benzenesulfonamide (SC558) discloses that the sulfonamide group of the inhibitor binds in the
side pocket adjacent to Val-523 in COX-2 (Figure 19).31 Access to this pocket is
constrained in COX-1 because of the extra steric bulk of Ile at this location. The binding
of the sulfonamide group of SC558 in this side pocket is expedited by the additional
substitutions of Val-434 and Arg-513.31 The sulfonamide group of SC558 interacts with
His-90, Gln-192, and Arg-513. The Arg-513 is preserved in all COX-2 enzymes and
provides a positive charge in the side pocket. SC558 forms hydrogen bonds between its
sulfonyl oxygens and His-90 and Arg-513, and the sulfonamide nitrogen hydrogen-bonds
to the backbone carbonyl oxygen of Phe-518. The bromophenyl ring of 4 binds in a
hydrophobic cavity formed by Ser-530, Leu-359, Trp-387, Tyr-385, Leu-384, and Phe381, and the trifluoromethyl group of the pyrazole ring binds in a small pocket provided
by Met113, Val-116, Val-349, Tyr-355, Leu-359, and Leu-531. Confirming the prior
mutagenesis studies on human COX-2, the crystal structure of mouse COX-2 and
compound 4 exhibits that the selective, time-dependent step in diaryl heterocycle
inhibition of COX-2 is probably the placing of the methyl sulfonyl or sulfonamide group of
the inhibitor past Val523 in COX-2 and into the side pocket. Val523 is replaced in COX-1
by the extra steric bulk of Ile-523.122-125
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Figure 19- Crystal structure of the celecoxib analogue, SC558, in the active site
of murine COX-2.31Compound SC558 is shown in green and is colored by atom. The key
active site residues important inhibitor binding is highlighted. Arg-120, Tyr-355, and
Glu-524 at the constriction site are shown in purple. Residues that constitute the small
hydrophobic binding pocket (Val-349, Leu-531, Ala-527, and Ser-530) and the COX-2
side pocket (Val-523, Arg-513, and Gln-192) are shown in yellow. Tyr-385 and Val-434
are also designated in yellow.

1.7.6. Naproxen and its analogs
Naproxen, a NSAIDs widely used for analgesic, anti-pyretic, and anti-inflammatory activity
(Fig. 20). It has been stated that it is active in the prevention of bladder cancer growth
even when administered several weeks after the tumor-initiating agent.126 Naproxen, is
non-selective COX inhibitor that binds both COX-1 and COX-2 and have gastrointestinal
side effects. In recent growing evidence suggests that it has no cardio vascular side
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effects when administered in the higher doses that deliver continued inhibition of platelet
COX-1 during the dosing interval (e.g.500 mg twice daily).127-129

Naproxen inhibited oCOX-1 with an IC50 value of 340 nM and mCOX-2 with an IC50 value
of 180 nM and showed greater than 80% inhibition in the presence of 500 nM AA (Fig.
21). Binding of Naproxen with COX — Aryl carboxylic acid inhibitors bind in one of two
orientations in the COX active site (Fig.20).130 Flurbiprofen attach canonically with its
carboxylate moiety ion-paired and hydrogen-bonded to the constriction site residues Arg120 and Tyr-355 (Fig. 20B).131-138 In contrast, diclofenac binds in a reversed orientation
in which its carboxylate is hydrogen-bonded to the side chains of Tyr-385 and Ser-530
(Fig.20B).139These two orientations can be differentiated by mutations of constriction site
residues
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FIGURE 20. Chemical structures of NSAIDs and crystal structures of flurbiprofen and diclofenac bound in mCOX-2
active site. A, chemical structures of naproxen, flurbiprofen, diclofenac, and indomethacin. The structures of flurbiprofen
(Protein Data Bank entry 3PGH; inhibitor carbon atoms colored gold) (B) and diclofenac (Protein Data Bank entry
1PXX) (C) bound at the COX-2 active site show the opposing binding modes that position their acidic groups either
coordinated to the constriction residues Arg-120 and Tyr-355 at the base of the active site or to the catalytic Tyr-385
as well as Ser-530 at the top of the pocket.130

Mutation of Tyr-355 to Phe in mCOX-2 ceased inhibition by naproxen (Fig.22A),130 while
mutation of Arg-120 to Gln slightly amplified the potency of inhibition as displayed by an
improved IC50 and a greater extent of inhibition (90%).Mutation of Arg-120 to Ala lead to
a complete loss of enzyme inhibition by naproxen (Fig. 22A). In concert, these outcomes
suggest that the carboxylate group of naproxen binds at the construction site in the
canonical orientation, coordinated to Tyr-355 and Arg-120. To thoroughly inspect the
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binding mode predicted from this studies Duggan and his co-worker.130 determined the
co-crystal structure of naproxen bound to mCOX-2 at 1.7 Å resolution, the highest

FIGURE 21. Effect of preincubation of enzyme and inhibitor on COX inhibition by naproxen.
Closed circles (F) represent incubations in which (0.05–25 nM) and AA (500 nM)
were added simultaneously to COX. For the incubations represented by open
circles (E), COX was preincubated with naproxen (0.05nM) for 5 min before the
addition of 500 nM AA. A is representative of incubations with oCOX-1, and B
represents reactions withmCOX-2. The reaction with substrate was allowed to
proceed for 8 s before quenching. Substrate consumption was analyzed by TLC
as described. Each data point is the mean of at least two experiments in duplicate.
Error bars, S.E. which eradicate inhibition by flurbiprofen but have no effect on inhibition
by diclofenac.130
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Table. 3a.COX inhibition studies of Naproxen.
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Figure 23- Crystal structure of naproxen bound to mCOX-2. A, difference electron
density map (F0Fc) contoured at 3.5α of the COX-2 active site prior to the addition of
naproxen to the model or modification of side chain positions in the binding pocket. 130
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resolution COX structure to date and among the highest resolution membrane. The
topology of the COX dimer and active site are like those of previous studies. To some
extent, amazingly, the residues lining the active site were exposed in single
conformations, even though the fact that many of them were surrounded only by solvent.
The resolution of this structure allowed the detection of a β-OG molecule lying on the
external side of the constriction, at the base of the funnel-shaped entrance to the active
site (lobby region), like to high resolution structures of COX-1(e.g. Protein Data Bank
entry 2AYL).140 A solvent molecule is frequently observed hydrogen-bonded toTyr-385
and Ser-530 in the active site; nevertheless, when this density was fitted with a water
molecule in the current structure, a 5α residual electron density peak kept on at that
position. When equipped with a chlorine atom, the residual peak gone, and the atom
polished to a temperature factor like neighboring protein and inhibitor atoms. A peak in
the great difference map at the same location delivered further indication that the peak
was a chlorine atom. While the physiological consequence of chloride binds in gat this
position is unknown, chloride ions have been used earlier to recognize the binding site of
molecular oxygen in various proteins, including dioxygenases.141-142 This increases the
probability that the Chloride ion may be revealing of the position of molecular oxygen
before assimilation into COX substrates. Strong electron density was detected for a single
orientation of naproxen binding within the COX-2 active site, making no contacts in the
COX-2 side pocket or lobby region (Fig. 23). As projected by the mutagenesis data, the.
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Figure 24. Inhibition of WT and W387F mCOX-2 by naproxen and
naproxen analogs. Following a 20-min preincubation of naproxen
(A), p-naproxen (B), or a p-methylthio naproxen(C) with mCOX-2(●)
Or W387F mCOX-2(O), [1-14 C] AA(50µM) was added and allowed
to react for 30s prior to termination with organic solvent. Concentrations of inhibitors ranged from 0.25 µM. Product formation was measure, by TLC as described. Each data point is the mean of at least
two independent experiments. Error bars, S.E
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binding mode of naproxen is alike that of other members of the 2-aryl propionic acid family
of NSAIDs with the carboxylate group of naproxen participating in hydrogen-bonding
inter-actions with Arg-120 (2.8 and 2.9 Å) and Tyr-355 (2.5 Å) at the base of the active
site. The remains of the interactions between the compound and protein were van der
Waals contacts. The (S)--methyl group of naproxen puts in the hydrophobic cleft adjacent
to Val-349, whereas the naphthyl backbone of naproxen makes hydrophobic contacts
with Ala-527, Gly-526, and Leu-352. Remarkably, the side chain of Leu-352 accepts an
alternate conformation from that observed in the co-crystal structures of flurbiprofen,
indomethacin, and diclofenac bound to mCOX-2. The p-methoxy group of naproxen is
focused on the apex of the COX active site and forms van der Waals interactions with
Trp-387 and Tyr-385. As mentioned above, the mCOX-2 naproxen crystal structure
shows that the (S)--methyl group of naproxen is oriented in a conformation like that of the
-methyl group of flurbiprofen and creates hydrophobic contacts with Val-349 as well as
Leu-359.131 Naproxen inhibited V349A mCOX-2 with a potency and extent of inhibition
similar to those of WT mCOX-2(IC50 3.5M, 75% inhibition), but the V349I and V349L
mutants were both more sensitive to inhibition (IC50 0.28 and 0.35 M, greater than 95%
inhibition. The rise in inhibition detected when naproxen was tested against V349I or
V349L could result from amplified hydrophobic interactions between the-methyl group
and residue 349.To trial this hypothesis, 2-des-methyl naproxen was tested against the
WT and V349I/L mutant enzymes. Elimination of the methyl group led to a substantial
reduction in inhibition of WT COX and the V349I/L mCOX-2 mutants (maximum inhibition
of 20% at concentrations up to 25 M) (Table 3a and data not shown). The accumulation
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of bulk at the-position also caused to a loss of potency because the-ethyl analog of
naproxen showed no inhibition of either wild-type COX-1 or COX-2 enzymes in our
standard IC50 assay (Table 1). Likewise, bulkier substitutions at the-position of flurbiprofen
impart a complete loss of inhibition of COX-131. Hence, the (S)-methyl group is a vital
determinant of naproxen efficacy, and it cannot be substituted with smaller (hydrogen) or
larger (ethyl) substituents. The naproxen-COX-2 crystal structure displays that the pmethoxy group interacts with Trp-387 by van der Waals associates with two carbon atoms
of the side chain, C2 (3.4 Å) and C 2(3.6 Å), the latter being the position of the side chain
unique spatially to tryptophans. Trp-387 is positioned at the top of the COX active site
near the catalytic residue, Tyr-385, and has been exposed to be an important residue for
the proper locating of AA within the active site to yield the cyclooxygenase product, PGG
2. The W387F mCOX-2 mutant enzyme procedures relatively little amounts of PGG 2 but
grown amounts of the uncyclized product, 11-hydroxyeicosatetraenoic acid.144 We
verified the W387F mutant for sensitivity to naproxen inhibition. A higher protein
concentration was applied as the mutant’s decreased catalytic activity. Naproxen had a
negligible inhibitory effect on W387F, displaying only 25% inhibition at 25M (Fig.22B).
The W387F mutation has not been studied with other inhibitors, so it was examined
against several other carboxylate-containing NSAIDs. Amazingly, the IC50 values for
diclofenac, flurbiprofen, and indomethacin against the W387F mutant enzyme were
similar to earlier reported values against wild-type enzyme (87,120, and 250 n,
respectively) (Fig. 22B).
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Diclofenac and indomethacin only form a single contact point to the Trp side chain, to the
C 2 position, one strictly imitated by phenylalanine.144While flurbiprofen also crates
interactions with both carbon atoms of the Trp residue, they originate from a phenyl ring
of the inhibitor that is earlier strengthened by other interactions, making the one with the
Trp possibly less important for binding. In naproxen, the oxygen of the p-methoxy group
lies within van der Waals contact range only of the Trp side chain. Thus, the interaction
between Trp-387 and naproxen appears to be unique among carboxylate-containing
NSAIDs.

To more investigation, the interaction between the methoxy group and Trp-387, two
naproxen analogs, were synthesized in which an ethyl or methyl thio group was replaced
for p-methoxy to present variations in size and polarity as well as to eliminate the
possibility of hydrogen-bonding interactions. The methyl-thio analog has been stated to
exhibit anti-inflammatory activity in vivo but has not been verified in vitro. The ethyl analog
has not been testified. Both the p-ethyl and p-methyl thio analogs could inhibit wild-type
mCOX-2 to the same extent as naproxen (IC50 0.67 and 0.77 M in our standard IC50
assay) (Table 3a). Remarkably, both analogs displayed a loss of potency compared with
naproxen when tested against oCOX-1 so that no IC50 value could be determined at
inhibitor concentrations up to 25 M. (Table 1). An increase in COX-2 selectivity at reduced
substrate concentrations (500 nM and 5M AA). More notable yet, both analogs inhibited
W387F as well as they inhibited wild-type enzyme (Fig. 24). The variance in sensitivity of
W387F mCOX-2 to naproxen and the p-ethyl and p-methyl thio analogs facilitate to
crystallize the complex of mCOX-2 with the p-methyl thio naproxen derivative. A structure
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of this complex was purified at 2.3 Å resolution (Fig.25). Like naproxen, the inhibitor is
bound completely within the main channel of the COX active site. The

Figure 25 Crystal structure of p-methylthio naproxen bound to mCOX-2. A,stereoview of the(Fo Fc )
difference electron map contoured at 3.0ճ prior to the addition of the inhibitor to the model.B,ste-review of
the p-methylthio naproxen analog bound within the mCOX-2 active site.The carboxylate partici-pates in
hydrogen-bonding interactions with Arg-120 and Tyr-355 at the base of the active site; this interaction is
represented by the dashed yellow lines.130
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nearest equivalent atoms (distance 0.2 Å) between the two compounds are the sulfur and
oxygen atoms of the p-methyl thio and p-methoxy groups, respectively. The carboxylate
tails of the compounds vary greatest in position, with the p-methyl thio-substituted
compound extending 0.5 Å less deeply into the binding site. The p-methyl thio naproxen
analog adopts a binding conformation similar to that of naproxen, maintaining many of
the same interactions with surrounding residues. For instance, the carboxylate makes
hydrogen-bonding interactions with Arg-120 (2.9 and 3.0 Å) and Tyr-355 (2.5 Å), and
the(S)--methyl group builds hydrophobic contacts with Val-349 and Leu-359. The
naphthyl backbone participates in van der Waals interactions with Ala-527 and Gly-526,
whereas the methyl thio substituent at the 6-position contacts Tyr-385 and Trp-387. In
contrast to naproxen, the p -methyl thio naproxen analog is not within van der Waals
distances of Leu-352. This difference arises from the Leu side chain exhibiting different
side chain conformation in the two structures, with that observed in the methyl thio analog
being consistent with that seen in the previously published NSAID mCOX-2 co-crystal
structures (three of four monomers). No explanation for the rotation of the residue in the
naproxen structure or its failure to rotate in the methyl thio derivative structure is readily
apparent. Comparison of the two crystal structures also indicates that Val-523 makes
hydrophobic contacts with the naphthyl backbone of the p-methyl thio naproxen analog
but does not contact naproxen. This observation results from the relative shift of the
compounds within the active site. kinetic studies as well as an extensive mutagenesis
study, exploration of the structure-activity relationship, and x-ray crystallography were
carried out to find out the molecular determinants of COX inhibition by naproxen. Key
interactions between the inhibitor and constriction site residues as well as a novel
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interaction with Trp-387 (Fig. 22) was identified. Substitution of an ethyl or methyl-thio
group for the p-methoxy substituent created COX-2- favoring naproxen analogs that were
unchanged by mutation of Trp-387 to Phe (Fig.24). X-ray crystal structures of both
naproxen and the p-methyl thio analog bound to mCOX-2. The combination of
mutagenesis, chemical elaboration of naproxen analogs and structural studies clearly defined the contribution of protein and inhibitor atoms to affinity (Figs.23 and 25).

Naproxen is a comparatively simple molecule with only three functional groups dispersed
on opposite ends of the naphthyl scaffold. Obtained data specify that each of these
substituents is essential for potent inhibition of both COX isoforms and that very slight
structural disparity is endured. Mutagenesis data indicate that one probability about the
nature of the interaction between the carboxylate moiety of naproxen and mCOX-2 is that
the carboxylate interacts with Arg-120 via hydrogen bonding rather than ion-pairing
interactions (Fig.22A). In divergence, the crystal structure of flurbiprofen in complex with
mCOX-2 shows that the carboxylate makes a salt bridge with the guanidinium group of
Arg-120.141 Besides, prior studies have revealed a 1000-fold increase in the IC50 value or
flurbiprofen against R120Q oCOX-1 compared with wild-type enzyme, signifying that ionpairing interactions are more vital for inhibition by flurbiprofen than naproxen.145
The-methyl group of naproxen looks to be involved in key interactions with the COX
enzymes. Initiation of a range of substituents of variable size and stereochemistry at the
-position recommends that the steric requirements for this interaction are rigorous, while
removal of the-methyl group also causes a remarkable loss of potency (Table 3a) Themethyl group leads to a small hydrophobic cleft below Val-349, which may help to anchor
naproxen within the mCOX-2 active site and thus strengthen the canonical binding
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orientation. The x-ray crystal structures of other 2-arylpropionic acids and the diaryl
heterocyclic compound, SC-558, bound to the COX enzymes direct that the-methyl group
(or 4-trifluoromethyl, in the case of SC-558) is bound in a similar style to the naproxen
structure.

131,146

Carboxylate-containing COX inhibitors without a methyl group in the-

position applies alternative interactions to bolster binding within the COX active site. For
instance, the indolyl-2-methyl group of indomethacin introduces into a hydro-phobic
pocket above Val-349 lined by Ala-527, Ser-530, and Leu-531 to form a firmly bound
complex. 131,147 Likewise, whereas diclofenac binds in an inverted orientation with the
carboxylate coordinated to Ser-530 and Tyr-385, a chlorine atom on the lower aniline ring
also supplements into the hydrophobic pocket above Val-349. A key interaction between
naproxen and Trp-387 was revealed during the mutagenesis screen by the indicating that
the W387F mutant was mostly insensitive to naproxen inhibition. This interaction seems
to be exclusive to naproxen as the same mutation had no considerable effect on inhibition
of mCOX-2 by diclofenac, flurbiprofen, or indomethacin (Fig.22B). The interaction with
Trp-387 may consequence from an amalgamation of hydrophobic packing of the methyl
group and electro-static interactions with the polarized methoxy group. This area of the
enzyme looks to be stable in its ability to bind functional groups; the p-hydroxy and pethoxy analogs were very weak inhibitors, however a methylene or sulfur substitution for
the oxygen atom of the p-methoxy group of naproxen created effective inhibitors of WT
mCOX-2. Contrasting naproxen, the p-ethyl and p-methyl thio analogs are potent
inhibitors of W387F mCOX-2. This recommends that either the interaction with Trp-387
is not essential to inhibition by the naproxen analogs or that they can interact more
efficiently with W387F COX-2 than is naproxen. Crystal structures of naproxen and the p-
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methyl thio naproxen analog display the substituents at the 6-position oriented in a very
like fashion at the top of the COX active site, delivering no definitive basis for differential
inhibition of W387F mCOX-2. Additionally, with the exemption of Leu-352, there are no
intensely different interactions through the rest of the active site. The substitution of Phe
for Trp at position 387 generates a larger active site for the mutant enzyme related with
WT mCOX-2. The capability of the p-ethyl and p-methyl thio naproxen analogs to inhibit
W387F mCOX-2as well as WT recommends that the analogs may be able to accept an
alternate conformation in the larger active site of W387F mCOX-2, rewarding for the loss
of the interaction with Trp-387 in the wild-type enzyme.

1.7.7. Oxicam and its analogs
Oxicams are a group of NSAIDs structurally related to 2-methyl-1,2-benzothiazineenolamide-1,1-dioxides and different types of substituted oxicams such as meloxicam,
droxicam and ampiroxicam are available in market. Oxicams are NSAIDs, containing a
fused thiazine dioxide ring and an extended carboxamide substitution (Fig. 26C).142 The
oxicam scaffold displays substantial flexibility and occurs as several protonation
tautomers throughout the keto/enol equilibrium.149 Isoxicam attaches to the COX-2 active
site using a remarkable binding pose—the murine COX-2isoxicam complex was
crystallized in the space group P21212 and diffracted to 2.0 Å applying earlier described
conditions.150 The electron density map of the COX-2 isoxicam complex was of exceptional
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Figure 26. Binding modes of NSAIDs in the COX-2 active site.A,mCOX-2 naproxen complex(PDB ID 3NT1)
reveals the H-bonding interactions(dashes) between naproxen(yellow) and the constriction site of mcox-2.B, COX-2
diclofenac complex(PDB ID 1PXX) showing the H-bonding interactions(dashes) between diclofenac(magneta) and Ser530 and Tyr-385.C,chemical structure of oxicams and other representative NSAIDs.148

quality to build in significant amounts of COX-2 (residues 33–583) and other protein substructural elements including protoporphyrin IX, the glycosylation sites at Asn-68, Asn144, Asn-410, and four -OG detergent molecules after molecular switch and structural
modification. Four detergent molecules are placed in the outer shell of the protein. There
are four molecules next to Lys-180 on the side of each monomer, which are shared with
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four other monomers from symmetric mates, counting as two detergent molecules for
each asymmetric unit. The other two detergent molecules are outside of Tyr-91 in helix B
in monomers B and C. No detergent molecules were observed in the lobby region or close
to helix D. The overall structure, consisted of the epidermal growth factor domain,
membrane binding domain, and the larger catalytic

Figure 27. Stereo-diagram of the electron density maps around isoxicam and meloxicam. A, a
simulated annealing composite omit map in the active site of mCOX-2, isoxicam complex. B, a simulated
annealing composite omit map in the active site of mCOX-2, meloxicam complex. C, a simulated annealing
composite omit map in the active site of mCOX-1, meloxicam complex. The simulated annealing omits
maps (34) are contoured at 1.5 in blue mesh; the key residues are illustrated with a stick representation of
the final modal (carbon in green, oxygen in red, isoxicam in orange); the molecule of isoxicam is colored in
orange and meloxicam is colored in wheat and yellow. 148
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domain, is like to the high-resolution crystal structure of the mCOX-2 naproxen complex
(PDB ID 3NT1), and few variations were observed among the four monomers in the
asymmetric unit with a root mean square deviation from 0.16 to 0.21 Å for the backbone
atoms. As such, the conformation of isoxicam in monomer A was used to designate the
facts associated with COX interactions and comparisons with other COX complexes. The
residues are categorized as the ovine COX-1 numbering system for clarity.131 Well
classified electron densities accounting for isoxicam were observed in the COX active site
of all four monomers in one asymmetric unit (Fig. 27A). Isoxicam binds in the COX
channel in an amazingly unique manner compared with other reported conformation
between helix 6 and helix 17 in the active site, adjusting a configuration with an
intramolecular hydrogen bond between the nitrogen atom from the carboxamide and the
4-hydroxyl oxygen of the benzothiazine. The drug interfaces with the hydrophobic COX
channel, primarily by van der Waals interactions. The only instant polar interaction
between isoxicam and COX is a hydrogen bond between the 4-hydroxyl group from
benzothiazine ring and Ser-530 with an actual distance of approximately 2.7 Å.
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Figure 28. Isoxicam binds to COX-2 in a novel pose via a two-water-mediated network
(stereo-diagram). The H-bonds are illustrated as dashes, the key residue is in green sticks,
water are in deep pink, and isoxicam is in orange.148

Remarkably, two finely ordered water molecules in the active site deliver additional polar
bridges between isoxicam and COX residues besides the 4-OH–Ser-530 interaction
(Figs. 27 and 28).148 The first water, which is positioned immediately above the
constriction site of COX, is approximately 3.0 Å away from both the oxygen of Tyr-355
and the guanidino nitrogen of Arg- 120, demonstrating that two hydrogen bonds are
formed. In the meantime, the same water molecule is within H-bond distances of the
oxygen of the carboxamide and the nitrogen atom in the thiazine ring of the inhibitor. At
the top of the active site, another water lies between Tyr-385 and Ser-530 and the
nitrogen atom of the isoxazole ring from isoxicam. The Binding of Isoxicam to COX-2
takes in Side Chain Rotation of Leu-531 and Structural Movement of Helix D—The
isoxicam complex discloses a small difference in the backbones of helices C and D in the
membrane binding domain and the side chain of Leu-531 in helix 17 compared with the
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1.7 Å resolution mCOX-2naproxen complex (PDB ID 3NT1).148 Because of steric
hindrance between Val-116 and one oxygen of the dioxide of isoxicam, helix D of COX-2

FIGURE 29. Structural changes in helices C and D of COX-2 upon the binding of isoxicam. The backbone atoms
of monomer A from mCOX-2 naproxen (PDB ID 3NT1) and isoxicam complexes are aligned. The helices are in a tube
representation, with the naproxen complex in gray and the isoxicam complex in green. 148

travels over 1.0 Å to hold the benzyl ring of the benzothiazine without further modifications
in the orientation of the corresponding residues in the helix (Fig.29). This kind of
movement was detected in the complexes of COX- 2AA and COX-21-AG (3MDL) but to
a lesser degree. This accommodation is also found in helix C, which undergoes a 0.5 Å
shift of the backbone from the original position. This flexibility of membrane binding
domain helices is steady with the observations made in the complex of human COX-2
with a zomepirac derivative, RS57067.151 In compare, helix 17, which also co-relates with
isoxicam, does not move. Though, the side chain of Leu-531 in this helix shows a different
rotamers (Fig. 30).148 The C atom of Leu-531 shifts approximately 3.5 Å away from the
active site toward the dimer interface, causing a possible CH- interaction between the C
atom of Leu-531 and the aromatic ring of the inhibitor with approximately 4.2 Å. This

59

movement releases a new hydrophobic pocket consists of Met-113, Val-116, Leu-117,
Ile-345, Val-349, Leu-531, Leu-534, and Met-535, which put up the rigid fused benzyl ring
of isoxicam (Fig. 30). Meloxicam Shows Two Conformations upon Binding to COX-2—
Meloxicam, an analog of isoxicam, is a 5-fold preferential inhibitor of COX-2 over COX1.152 To study why meloxicam is a favored COX-2 inhibitor whereas isoxicam is a
nonselective one, the mCOX-2meloxicam complex was determined by x-ray
crystallography.The 2.45 Å resolution structure is of appropriate value to include most of
the components including the EGF domain, membrane binding domain, the catalytic
domain, and glycosylation sites at Asn-68, Asn-144, and Asn-410. Yet, the detailed
orientation of the carboxamide moiety of meloxicam could not be determined. Both the
sulfur and nitrogen atoms of the thiazole ring are good candidates to make an alike
hydrogen bonding network between the coordinated water and the catalytic apex. The
electron density around the methyl group on the thiazole ring is inadequate to distinguish
the conformation in the complex (Fig.27).148
This statement recommends that two conformations are existing in the m COX-2
meloxicam complex. In the first conformation, the methyl group points down toward the
entry of the active site. The nitrogen of the thiazole ring is approximately 2.8 Å away from
the water, while the sulfur atom interacts with Val-523 and Phe-518 in this conformation.
In the second conformation, the methyl group points up and binds in a hydrophobic pocket
comprising Leu-384, Trp-387, Phe-518, and Met-522. In this conformation, the sulfur of
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FIGURE 30. Leu-531 opens a new binding pocket for isoxicam in the mCOX-2 active site. A, stereo-diagram of
the surface representation around isoxicam (orange sticks and balls). B, same view of the binding pocket around the
naproxen (yellow sticks and balls) complex (PDB ID 3NT1). C, binding pocket around 1-AG (yellow sticks and balls)
complex (PDB ID 3MDL). The interacting residues are in green, and Leu-531 is highlighted in blue; the surrounding
surfaces are shown in semi-transparent gray.148
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FIGURE 31. Stereo-diagram of meloxicam bound to the mCOX-2 active site. The protein residues are shown as green sticks
and balls, the coordinated waters are in spheres, and the methyl-pointing-down conformation of meloxicam is colored in cyan
and a green dash for the interaction with the water; the methyl-pointing-up conformation is in wheat with the corresponding Hbond in red. Other hydrogen bonds are illustrated as black dashes. 148

the thiazole group interacts with the water molecule at an effective distance of 3.3 Å.
Based on the quality of the electron density map or the chemical plausibility for satisfying
hydrogen bonding and hydrophobic interactions it is not possible to eliminate any
confirmation. Therefore, both conformations are counted in in the final structure (Fig. 30).
Other than this conformational flexibility, meloxicam binds to the COX active site in the
same mode as isoxicam with hydrogen bonding to Ser-530, hydrogen bonding to two
coordinated waters complexed to Tyr- 385/Ser-530 and Arg-120/Tyr-355, and the new
hydrophobic pocket generated by the movement of Leu-531. Subtle Structural Features
around Phe-518 distinct the selectivity of meloxicam for COX-2 over COX-1, Provided
that New Structural Insights on Selectivity—The structure of ovine COX-1 in complex with
meloxicam was solved at 2.4 Å resolution. The binding pose of meloxicam in the COX-1
active was similar to that of meloxicam bound to COX-2 (Figs.27 and 32). In vitro assay,
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FIGURE 32. Inhibition of mCOX-2 and mutants by meloxicam. A, inhibition profiles of meloxicam toward oCOX-1, mCOX-2, and
its mutants. B, structural difference in the active site between oCOX-1 (slate sticks) and mCOX-2 (red sticks) highlighting the
changes in residues 434, 518, 513, and 523. Points in A are from triplicate measurements and are depicted as the mean S.E. (error
bars). The backbone atoms of oCOX-1 meloxicam structure are aligned with those of the mCOX-2 meloxicam complex. Only the
up conformation of meloxicam from mCOX-2 complex is represented for clarity.148

meloxicam displays an IC50 of 150 nM toward wild-type recombinant mouse COX-2 while
it shows an IC50 of 990 nM for native ovine COX-1 (Fig. 32), Physically, COX-1 and COX2 share most secondary characteristics with slight changes in the active site that include
I434V, H513R, and I523V COX-13COX-2 substitutions. 131,147 The triple COX-2 mutant of
V434I/R513H/V523I exhibited a reduced inhibition by meloxicam with an IC50 of 1.22 M,
which is like wild type ovine COX-1 (Fig. 32). As Arg-513 is placed in the side pocket of
COX-2 and hardly interacts with meloxicam in the crystal structure, then inhibition studies
on the mCOX-2 mutants of V434I and V523I was concentrated. The V523I mutant
displayed potent inhibition by meloxicam with an IC50 of 174 nM. But, meloxicam inhibited
the V434I mutant with an IC50 of 1.4 M. This study discloses that mutation of Val-434 to
Ile at position 434 in murine COX-2 is sufficient to decrease the potency of meloxicam
COX-2 inhibition to that of ovine COX-1 (Fig. 32). The extra carbon in the side chain of
Ile- 434 in the secondary shell in COX-1 initiates Phe-518 to move toward the main
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channel further than in COX-2 in which a valine is located at the same position131.
Therefore, the selectivity of meloxicam for COX-2 is due to the subtle structural features
about Phe-518, wherever several rotamers of Phe-518 are bestowed in COX-1 and COX2 structures because of the difference of secondary shell residues Ile-434 for COX-1 and
Val-434 for COX-2.
Oxicams bind in the cyclooxygenase channel with an innovative pose compared with
earlier described NSAID binding modes, in which the carboxylic acid of the inhibitor
interacts either in the canonical mode with Arg-120 and Tyr-355131,147 or in the inverted
binding mode with Tyr-385 and Ser-530.131 On the other hand, oxicams interact with all
four of these residues, Arg-120, Tyr-355, Tyr-385, and Ser-530. Nevertheless, apart from
a direct hydrogen bond between the 4-hydroxyl group of the benzothiazine moiety and
Ser-530, the oxicams do not openly interact with any of these residues by ion pairing or
hydrogen bonding. But, they interact indirectly by bridging with two tightly bound waters:
a tetrahedrally coordinated water bound to Arg-120 and Tyr-355 and a trigonally
coordinated water bound to Tyr-385 and Ser-530. Besides, the water bridge between the
carboxamide and Ser-530 and Tyr-385 delivers the first structural clarification for the
study that all oxicam drugs contain a heteroatom at the 1position in the carboxamide
moiety. The binding of oxicams is go together with by variations in protein conformation,
explaining an induced fit mechanism, which is unusual in the interaction between COX
and NSAIDs. This comprises the rotation of the side chain of Leu-531 and a modest
movement of helix D. The rotamer of Leu-531 in the oxicam complexes is like that
detected in the nonproductive conformations of mCOX-2AA mCOX-21-AG (36), and
G533V-AA complexes153, but such a rotation has not been noticed in the binding of any
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NSAIDs. For isoxicam, it opens a completely new sub-pocket in the COX active site (Fig.
28), which may characterize a target region for drug discovery. It is an important
remarking that the variance in orientation of Leu-531 in the complexes of oxicams or 1AG is mainly a result of structural fluctuations among the complexes and changes in
quality of the electron densities around the region in the two complexes. The second
isoxicam-induced protein conformation is the over 1.0 Å movement of helix D as a retort
to steric hindrance between the oxygen of the sulfonyl dioxide and the side chain of Val116. This extra confirms the flexibility of the membrane-binding domain of COX-2.147 The
identification of this novel binding approach offers exact interactions between oxicams
and COX-2 and atonements the prior computational models for oxicams.152 The strain of
forecasting the oxicam-protein interactions arises for several reasons: the oxicams may
exist in several tautomers; the two highly coordinated water molecules in the active site
are nearly impossible to predict, as the representation and role that water plays in ligandprotein interactions reduces the effective ness of docking predictions154; and the
recognition

of the movement

of Leu-531 in

COX-2 complexes was only recently

reported.154 These complex trepidations in the COX-2 active site existing an array of
computational problems that complicate the forecast of oxicam binding modes. Even
though most structure-activity relationship studies of oxicams were finished before the
discovery of COX-2 and before the recognition of the importance of COX-2 in
inflammation, several lines of sign show that the binding mode labelled here fits well with
available studies and the pharmacological characterizations of oxicams. The methyl
substituent at the 2 position of the benzothiazine is optimal for anti-inflammatory activity.
This methyl group interacts with residues Leu-359, Tyr-355, and Val-349. Replacement
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of this methyl group with any other substituent (e.g. H, benzyl, allyl , ethyl, propyl) either
removes the interaction between the protein residues or introduces steric bulk that
prevents binding in this region. Thus, such substituents were less active than the 2-methyl
compounds. Among analogs of 3-carboxamides with anilide substituents, metasubstituted anilides display more potent activity than para-substituted anilides. The metasubstitution pattern mimics the methyl-up conformation of meloxicam and fits quite well
within the pocket formed by Leu-384, Tyr-385, Met-522, Phe- 518, and Trp-387 in the
crystal structures. Finally, in a study of thieno [2,3, -e] thiazine analogs, the 2-pyridyl
carboxamide (tenoxicam) presented better activity compared with isomeric 3- or 4-pyridyl
amides, consistent with the essential role of a H-bond acceptor for ligand binding to the
water coordinated to Tyr-385 and Ser-530. Meloxicam displays modest COX-2 selectivity
with an IC50 of 150 nM for COX-2 and an IC50 of 990 nM for COX-1 in our in vitro assay.
In mutagenesis experiments recommend that the preference of meloxicam for COX-2 is
not because of the substitution of Ile-523 in COX-1 for Val-523 in COX-2, which
responsible for the selectivity of inhibition by rofecoxib and celecoxib, but somewhat
subtle changes around Phe-518 produced by the substitution of isoleucine to valine at
residue 434 in COX-2 (Fig.33). The added methylene group of Ile-434 in oCOX-1 drives
Phe-518 into the main channel of the cyclooxygenase active site and shrinks the available
space close to the thiazole ring of meloxicam. This modification of the orientation of Phe518 between COX-1 and COX-2 structures was first defined in the complex of COX-2
with SC-558, a diaryl heterocyclic COX-2 selective inhibitor.131It was recommended that
the addition of the phenyl sulfonamide group into the side pocket of COX-2 is helped by
the movement of Phe-518 to accommodate the movement of Val-523. This hypothesis
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was not verified with mutagenesis experiments. The probable bangs between the 4methyl group of meloxicam and Phe-518 propose a direct interaction of Phe-518 with
inhibitor in the case of meloxicam as resisted to protein movement in the case SC-558.
Thus, subtle environmental differences around Phe-518 adjust the COX-2 selectivity of
different classes of inhibitors. Together, the crystal structure of recombinant murine COX2 in complex with isoxicam and meloxicam existing here delivers the first structural
description for the binding mode of the oxicam class of NSAIDs and discloses a novel
binding mode in the cyclooxygenase channel via a two-water-mediated network
characterized by interactions with formerly recognized binding residues all over the main
channel of the active site. Additionally, this binding mode involves the movement of Leu531 to accommodate the inhibitor. This is the first time Leu-531 has been known as an
interacting residue in NSAID binding although it is involved in binding certain substrates.
Moreover, mutagenesis studies direct that the molecular basis for the preferential
inhibition of COX-2 by meloxicam is because of the subtle differences around Phe-518 in
the active site. In conclusion, this structural description of COX-2oxicam complexes
clarifies previous structure-activity studies of oxicams, directs new substitutions within the
oxicam scaffold, and finds a new pocket around Leu-531 for development of novel
NSAIDs.

1.7.8 NSAIDs as anti-cancer agent

Infections and inflammation link to cancer. A possible relation between inflammation and
the growth of pre-cancerous trauma in different cells have been recognized. The
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researcher has found that inflammation in prostate, colon, and pancreas will increase
14%, 25% and 20% risk of prostate, colon and pancreatic cancer respectively.155
Therefore, inflammation seems to initiate or induce growth of tumor cells. Chronic
inflammation depicted by infiltration of mononuclear immune cells (including
macrophages, lymphocytes, and plasma cells), tissue destruction, fibrosis, and increased
angiogenesis. Due to Chronic inflammation, the initiation and propagation of tumor cells
such as intensified genomic damage, augmentation of DNA synthesis, cellular
proliferation, disruption of DNA repair pathways, inhibition of apoptosis, and the promotion
of angiogenesis and invasion occur in cells. Pro-inflammatory molecules, such as
cytokines, inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), and
NF-kB are upregulated in chronic inflammation. All these processes simultaneously
ensure a suitable microenvironment for the exponential growth of tumor cells. So,
inflammation may give both the key mutations and the compatible environment to
enhance tumor growth.
In Chavey et al., it is mentioned that some cytokines, including IL-6, IL-8, G-CSF
(granulocyte colony stimulating factor), IFN-γ (interferon-γ), and MIP-1β (macrophage
inflammatory protein- 1β), were found to be more abundant in breast carcinoma than in
normal breast tissue. Nowadays, Researchers also have found that COX1 and COX2
enzymes are overexpressed in different tumor cells, for example colorectal, gastric,
esophageal, hepatocellular, pancreatic, head and neck, non-small cell Lung, ovarian,
breast, bladder, cervical, endometrial and skin Cancer cells.156
Long term use of aspirin (a Non-selective NSAID) and other NSAIDs reduce the incidence
of colorectal esophageal, breast, lung and bladder cancers. In 1990, indomethacin was
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used as an anti-tumor agent in over hundred patients in an advanced stage of colorectal
cancer and liver, Pancreatic cancer and primary gastric cancers and found that patient
survived six months more than the expected. Hong-Mei Wang et.al mentioned that
Indomethacin suppressed the growth of colon cancer via inhibition of angiogenesis in
vivo.157
Selective COX-2 inhibitor celecoxib Inhibits AKT signaling and induces apoptosis of
human colorectal and prostate cancer cells in vitro.158 Researchers also have found that
COX2 inhibitors also reduce the growth of human breast & lungs cancer and COX1
inhibitors inhibit the progression of human ovarian as well as colon cancer. Sue-Lin Fu
et.al159 have found that COX-2 inhibitors have anticancer effects on gastric cancer.
Inhibitors show significant roles in angiogenesis and infiltration or metastasis of stomach
carcinoma. The anticancer effects of COX-2 inhibitors may involve inducing apoptosis,
suppressing proliferation, reducing angiogenesis and weakening invasiveness.
Researchers have identified that selective COX-2 inhibitor, Celecoxib active against
breast cancer in vitro and vivo.160-161 In a combination of NSAIDs and chemotherapeutic
agents, the scientist has obtained synergetic effects on tumor development and
progression in vitro models 3. In 1994, Teicher et al. performed a Lewis lung carcinoma
model and identified a positive effect of using nonsteroidal anti-inflammatory drugs with
chemotherapy in the primary and last stage of non-small cell lung cancer. It is proven that
in combinations of a COX inhibitor with chemotherapeutic agents such as cisplatin and
cyclophosphamide led to tumor growth delay and a decreased number of lung
metastases.162Moreover, researchers have found a synergistic effect on human NSCLC
cell lines by using sulindac sulfide (COX-1 and -2 inhibitor) with the cytotoxic agents
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paclitaxel and docetaxel.163In mouse model study, it is found that non-selective COX
inhibitor SC-236 drug prevents tumor growth and increases the effect of radiotherapy
without affecting the radio response of the standard tissue.122Pyro et al. studied and
identified the radiation-enhancing effect of COX-2 inhibitors in vitro as well as in vivo in
human lung and colon cancer.164
COX inhibitor, nimesulide showed inhibition of proliferation and decreased the doses of
different anti-tumor drugs such as cisplatin, VP-16, and docetaxel.165
NSAIDs can also use for reduction of side effects associated with chemotherapy. When
celecoxib applied with capecitabine for metastatic colorectal cancer chemotherapy, the
side effects (such as diarrhea and the hand–foot syndrome) decreased in greater
extent.166 In colorectal cancer xenograft mouse model (HT29 cells and Colon-26 cells in
nude mice and BALB/c mice) studies, it was found that Celecoxib enhanced CPT-11
cytotoxicity and also reduced the difficulty of CPT-11 induced diarrhea.167
Celecoxib increases CPT-11 cytotoxicity in colorectal cancer xenograft mouse models
(HT29 cells and Colon-26 cells in nude mice and BALB/c mice), but it can also decrease
the severity of CPT-induced diarrhea. The remission of diarrhea recommends an
inflammatory part of the pathogenesis of CPT-11 induced delayed diarrhea. Trifan et.al
identified that COX-2 enzyme was expressed after treatment of rat colon cancer cells with
CPT-11 and PGE2 synthesis was enhanced.168
Through cell line model study, it is clear that NSAIDs are also active against the tumor.
NSAIDs can do prevention of angiogenesis, proliferation, invasive growth, and induce
apoptosis in cells in a COX2 dependent or independent manner. Anti-cancer activities of
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NSAIDs follow verities of the mechanism. But, the key mechanisms are the prevention
of prostaglandin E2 (PGE2) formation and transcriptional activity of COX2 inhibition.
Moreover, by clinical trials, the required doses of NSAIDs that induce COX2 free path for
causing anti-tumor activities are not found yet.
EGFR (epidermal growth factor receptor) has a significant role in the regulation of normal
cell growth, apoptosis, and other cellular activities. Different types of cancers such as
non-small-cell lung cancer, pancreatic cancer, breast cancer, colon cancer and some
other cancers that are caused by upregulation of EGFR. The receptors are continuously
and abnormally activated by mutation of EGFRs. EGFR inhibitors used as anti-cancer
agents. Since COX produces PGE2 which activates the EGFR, in combination therapy
both inhibitors play a synergetic role in cancer treatment. When Celecoxib was used with
Herceptin (a monoclonal antibody against the ErbB receptor HER-2/neu) in vitro and in
the vivo cell proliferation assay, Mann et al. found a positive effect on control of colorectal
carcinoma cell growth. In colorectal cancer cell growth reduction, COX-2 and HER2/neu
inhibitors work together more efficiently. In a murine model study of human FAP, it is
identified that in a combination of sulindac (a COX inhibitor) with EKI-569(an irreversible
inhibitor of EGFRK) furnish protection to intestinal neoplasia.169
1.7.9. NSAIDs to circumvent resistance to conventional chemotherapy
At First, NSAIDs were combined with traditional chemotherapeutic agents to overcome
cancer chemotherapy resistance mechanism and found that NSAIDs increased the
efficacy of the chemotherapeutic agents. In the mitochondrial level, Bcl-2 family of pro
and anti-apoptotic proteins stimulates or inhibits apoptosis. Bcl-2 family members impart
a clinically important resistance to chemotherapeutic agents in some hematologic and
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solid malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia,
chronic myeloid leukemia, chronic lymphoblastic leukemia, multiple myeloma, prostate
cancer, malignant brain tumors, and neuroblastoma.170-175 Downregulation of Bcl-2
amplifies toxicity for chemotherapeutic agents in some tumor cell lines.176-177COX-2
selective NSAIDs such as SC-58125 and NS-398 can down-regulate Bcl-2 and
consequently induce apoptosis in colon and prostate cancer cell lines.178 In HCT116
colorectal carcinoma cells, it is found that an increase in pro-apoptotic Bax protein and a
decrease in Bcl-XL protein induces apoptosis.179 Through Bak and Bax up-regulation,
mitochondrial membrane potential loss and activation of caspase-3.180-181(Fig-26)
Celecoxib, aspirin, and indomethacin might induce apoptosis. Bcl-2 family of antiapoptosis proteins can also be downregulated by inhibiting Akt signaling. Akt/PKB is a
serine/threonine protein kinase that works as an important regulator of cell survival and
proliferation. It has been revealed that PI3K/Akt signaling components are frequently
altered in human cancers. Another mechanism of amplified Akt signaling is the reduced
activity of Akt regulatory proteins. Akt phosphorylation is linked with phosphorylation and
thus inactivation of the pro-apoptotic proteins Bad and caspase-9. Phosphorylated Bad
cannot bind to Bcl-2, whereas phosphorylated caspase-9 cannot be activated lead to a
reduced activity of mitochondrial apoptosis182-183. Celecoxib and aspirin inhibit Akt
phosphorylation and resulting in apoptosis in the human A549 non-small cell lung cancer
cell line.184 In an in vivo model of spontaneous metastatic breast cancer, it is found that
celecoxib-induced apoptosis correlated with a significant decrease in Akt activation.185
Celecoxib also blocked Akt phosphorylation and kinase activity in cultured human C611B
cholangio carcinoma cells, which associated with Bax translocation to mitochondria,
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cytochrome c release into the cytosol, followed by activation of caspase-9 and caspase3. The addition of PGE2 to these cells suppressed the apoptotic activities of celecoxib.186187

The epidermal growth factor receptor (EGFR; erbB1), a member of the tyrosine kinase

receptor family composed of HER-2/neu (erbB2), erbB3, and erbB4.188-189 The ErbB
receptors are located at the cell surface and connect to a common structure constituted
of an extracellular ligand binding domain, the transmembrane segment, and an
intracellular tyrosine kinase domain.190 When LS-174T colorectal carcinoma cells
exposed to PGE2 and display rapid induction of Akt signaling, Akt activation can be
stopped by EGFR-specific tyrosine kinase inhibitors. This rapid transactivation of the
EGFR appears through an intracellular pathway because inactivation of EGFR ligands
with inhibitory antibodies did not inhibit PGE2-mediated Akt activation (Fig. 33).191 In
Caco-2, LoVo and

HT-29

colon

cancer

cell

lines PGE2

expression induces

phosphorylation and consequently activation of downstream targets of the EGFR pathway
such as ERK2.When selective inhibitors activated EGFR activation, PGE2 induced ERK2
activation reduced extensively.192 PGE2, still, can also directly activate EGFR signaling
and thus promote cell proliferation.190,191 The mechanism involves PGE2-mediated
metalloproteinase activation resulting in shedding of EGFR ligand from the plasma
membrane and consequently, stimulated EGFR signaling. Another mechanism includes
activation of the cAMP/protein kinase A pathway directing to enhanced expression of
amphiregulin, a ligand of EGFR.193 The TNF family of death receptors and ligands is a
family of apoptosis-inducing proteins. Several human death receptors have been
recognized.194,195 Apoptosis is activated upon binding of specific TNF superfamily ligands,
such as TNF, FasL (CD95L/APO-1L) or TNF- related apoptosis-inducing ligand (TRAIL),
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Figure 33- Akt can be upregulated by COX-2, while both Akt and COX-2 are inhibited by NSAIDs. Inhibition of Akt
prevents phosphorylation and inactivation of Bad and caspase-9 resulting in decreased apoptosis. Different NSAIDs
can modulate expression of Bcl-2 family members. Modulation of Bcl-2 family members involves downregulation
of anti-apoptotic members and upregulation of pro-apoptotic members.

to a receptor TNFR1, TNFR2, Fas or DR4 (TRAIL-R1/APO-2)/DR5 (TRAILR2/ KILLER/
TRICK2), respectively. Moreover, attaching to the agonistic receptors TNFR1, TNFR2,
Fas, DR4, and DR5, FasL can also bind to the soluble inhibitory decoy receptor, DcR3,
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whereas TRAIL can bind to membrane-bound DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4),
which both lack functional death domains and are thus unable to induce apoptosis. TRAIL
also attaches to a soluble TNF family receptor, osteoprotegerin. But, the physiological
importance of this interaction appears to be nominal. Upon trimerization of the death
receptors, an intracellular death inducing signaling complex (DISC) is produced that
consists of trimerized receptor molecules and recruited TNF receptor associated death
domain (TRADD) or Fas-associated death domain (FADD) and procaspase-8 molecules.
Subsequent DISC gathering a cascade of effector caspases and substrates are triggered.
The nucleus is compressed and split, the cytoplasm is reduced, and apoptosis induction
is completed.196, 197
Many studies discovered that death receptor apoptosis pathways are involved in
chemotherapy-induced apoptosis. NSAIDs are also able to induce apoptosis via the
TRAIL and Fas signaling pathways as was identified by Han et al. They presented that
FADD is required to induce apoptosis with indomethacin in Jurkat cells.198 Indomethacin
also induces apoptosis in a developed doxorubicin resistant SCLC cell line via death
receptor signaling.199 In a hepatocellular cell line model, exposure to NS-398 caused Fas
ligand upregulation and Fas-mediated apoptosis in COX-2 overexpressing cell lines.200
TRAIL receptor DR5 was upregulated in colon, prostate, and NSCLC cell lines after
contact to sulindac sulfide and celecoxib, respectively. These NSAIDs induced apoptosis,
which was further enlarged in combination with TRAIL 201,202 (Fig. 27). COX-2 inhibition
can be straightway involved in enhancing TRAIL-mediated apoptosis as demonstrated in
HT29 colon cancer cells. Both COX-2 inhibition and COX-2 downregulation induced
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clustering of DR5 at the cell surface and reorganization of the death-inducing signaling
complex components (DR5, FADD, and procaspase-8) into cholesterol-rich and
ceramide-rich domains.203 Also, the upregulation of DR5, NSAIDs especially, sulindac
might also increase TRAIL-sensitivity by down-regulating surviving expression.204–207
Other downstream components of the apoptosis pathway such as anti-apoptotic
members of the Bcl-2 family can be disturbed NSAIDs as well. For example, the reduction

Figure 34- Death receptor-mediated apoptosis is facilitated at different levels by NSAIDs. NS-398 increases
FasL expression, sulindac sulfide increases DR5 expression and indomethacin and sulindac sulfide can
activate the intracellular part of the death-inducing signaling complex. Inhibition of I_B kinases by selective
and non-selective COX inhibitors results in decreased NF-_B in the nucleus and subsequently in a
decreased transcription of pro- and anti-apoptosis proteins in expression of the anti-apoptotic protein BclXL in Bax-proficient HCT116 cells by sulindac sulfide enlarged TRAIL induced apoptosis. The impact of
sulindac sulfide on Bcl-XL is probably due to a reduction in NF-_B activity208.
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1.8 Synthesis of BRL-37959

BRL-37959 was synthesized by Boyle and his coworkers of using expensive starting
material and overall yield of the process was only 5%. This synthetic method is shown in
Scheme 1.

Since the compound seemed a potent NSAID, Becham Research Laboratory (BRL)
developed second method(scheme-2) to produce BRL-37595. The overall yield of the
method was also ≤ 5%. Then they developed also third method to (scheme-3) synthesize
the compound but yield was not improved.

1.8.1. Direct Friedel-Crafts benzoylation of 5-chlorobenzofuran-3-ethyl
ester (3)
Friedel-Crafts benzoylation was done on 5-chlorobenzofuran-3-ethyl ester directly
(scheme-4) gave benzoylation exclusively at the Ortho-position (i.e., 33) in 20% yield and
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was not investigated further. This result is supported by previous researchers.217 A long
with the method above, the method of Sharghi182 et al. was used ZnO as a catalyst
(Scheme: 5). This process was unsuccessful, and only starting materials were recovered.

1.8.2. Attempts to benzoylate 5-chloro salicyalldehyde (1)
A Fries method was also tested to benzoylate 5-chlorosalicylaldehyde as shown in
(Scheme 4) below. This method also proved failed when 5-chloro salicylaldehyde was
used. When only salicylaldehyde was used, the reaction gave low yields (i.e., < 5%) of
salicylaldehyde benzoylated at the para position.

1.8.3. Exploration of other methods

While direct benzoylation of 5-chlorobenzofuran was not feasible due to the above result,
investigation of previous work, other than that presented earlier, disclosed two interesting
methods that might have likely in forming the elusive 3-formyl-2-hydroxy benzophenone
as shown in Figure 35. Synthesis of 3-formyl-hydroxy benzophenone would tolerate for
subsequent transformation into a benzofuran-3-ethyl ester derivative. Since this
compound could be proposed through only two possible methods, an approach was made
to synthesize 3-formyl-2-hydroxybenzophenone. The first method included a novel Mgmediated formylation of 2-hydroxybenzophenone and the second method involved either
a Duff formylation of salicylic acid as shown in Scheme 6.217
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Approach 1: Formylation

Approach 2: Benzoylation

Figure 35- Two possible approaches to produce BRL-37959
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Scheme 6: Fries rearrangement
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Scheme 7: The Duff formylation of salicylic acid

The second method showed difficult when using the Fries rearrangement and besides
required protection of the aldehyde functional group. Several protection approaches were
investigated using salicylaldehyde as the prototypical substrate. Some of these protected
salicylaldehyde derivatives were tried using diethanolamine, glycol, or methanol to give
the corresponding acetal or oxazolidine derivatives. Remarkably, the addition of
diethanolamine to salicylaldehyde gave a high yield (>90%) after azeotropic distillation of
oxazolidine. Attempted protection with ethylene diamine gave an imine. Furthermore,
protection of the phenolic group by replacement with methoxy was active using oanisaldehyde. In addition to, complete reduction of salicylaldehyde to salicyl alcohol (i.e.,
2-hydroxybenzyl alcohol) was also attempted using sodium borohydride, followed by
treatment with acetone in the presence of a catalytic amount of aluminum chloride (AICI3).
This reaction created a protected dioxin compound which subsequently polymerized
heavily on treatment under the resulting Friedel-Crafts conditions employed
duringbenzoylation. The overall structures of the protecting groups and the final reaction
scheme are illustrated in Figure 24 below. None of the protection plans outlined in Figure
24 gave benzoylation.
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Figure 36-Protecting group employed in unsuccessful o-benzoylations.

1.8.4. Negative results for acylation at the ortho position.
It seems that there still does not exist a cheap method to produce acylation at the ortho
position of salicylaldehyde derivatives. Later a review of the literature, only two potential
literature methods were found. Both procedures were investigated with no positive
outcome. Details of each of these methods are included in Figure 37.
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Figure 37- Known literature methods to synthesize 3-formyl-2-hydroxybenzophenones.
Elizalde-Herrera’s method.

Elizalde-Herrera's method is straightforward and inexpensive. It is like the Fries
rearrangement above. The method seemed to be the same as that did in the Fries
rearrangement. Discussion with Elizalde himself produced no help in attaining the
compound. The only proof of benzoylation at the para-position of salicylaldehyde occurs.
Unfortunately, several attempts at using Elizalde-Herrara's method gave no ortho product
- only substitution at the para-position. The utility in the investigation of Elizalde-Herrara's
method ensured to have one positive outcome as it allowed for improvement in yield for
acylation at the para-position as shown in Scheme 8.

Scheme 8: Improvements upon Elizalde-Herrara's method of p-aroylation of
Salicylaldehydes

~50%
The method of Dey was, unfortunately, not found to be passable either. Dey's method
initially looked to be promising, though more complicated and expensive. Dey's process
was nevertheless, concluded as suitable to produce a valid reference sample for ongoing
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research. The method needed the use of 3-formyl-salicylic acid from the formylation as
mentioned earlier procedure of Duff and Bills217 (Scheme 7). Per the method of Kida218
et. al., 3-Formyl-salicylic acid is then allowed to react in the presence of warm aqueous
Na2C03 and ethylenediamine in the presence of 1 equivalent Ni(ll) acetate tetrahydrate
for approximately one hour as shown in Scheme 8. Difficulty rises in this procedure from
the formation of the highly stable (and unreactive) binuclear complex also shown Scheme
9.
Scheme 9: Preparation of the Nickel complex used by Dey

N.R
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1.8.5 Improved methodology
A developed methodology utilized the use of 2-benzyl-4-chloro-6-formyl-phenol (i.e.
Chlorophene) as a substrate (Figure 38). This method proved convenient as it completely
avoids the use of acylation and instead relies on a strategy of benzylic oxidation. The
Figure 38-Route to BRL37959 showing proposed oxidation

improved methodology is also cheap and high-yielding, although it is apparently limited
in comparison to the acylation approach due to the requirement of para-substituted
phenol derivatives. As shown in Figure 17, the reaction is high-yielding and successful up
to oxidation of the benzylic carbon. No oxidation was observed at the benzylic carbon
86

despite several strategies using oxidizing methods such as phase transfer catalysis (PTC)
with NaOH and ambient air (02); NaOCI; H202; and Mn02.

1.8.6. Synthesis of Chiral BRL-37959
In 2012, Bongen, Patrick, and his co-workers synthesized chiral BRL-37959 by direct
Friedel-Crafts benzoylation of 5-choro benzofuran-3-ethyl ester (scheme- 9) and found
benzoylation exclusively at the Ortho-position (i.e., 33) in 30% yield. They followed
Hossain et al. to synthesize racemic 5-chlorobenzofuran-3-ethyl ester.
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Results and Discussion
2.1. Previous work
2.1.1. Synthesis of BRL-37959

In 1986, Boyle32 and her co-worker synthesized BRL-37959 (5) and found that the
compound was active as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The overall
yield of the method was only 5%(Scheme 9). In the First Step, 6-chloro-4-chromanone
(1) was treated with thallium trinitrate {Tl(NO3)3} on K-10 clay. Then obtained yellow solid
was dissolved in MeOH and reacted with Na2CO3 followed by the treatment with EtOH
and HCl to form Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) in a 15% yield. In
reduction,

2

was

treated

with

Mg

in

MeOH

to

give

methyl

5-chloro-2,3-

dihydrobenzo[b]furan-3-carboxylate (3). Trans-esterification of 3 produced ethyl 5-chloro2,3-dihydrobenzo[b]furan-3-carboxylate (4). In benzoylation, 4 was treated with powdered

Scheme 1. First Method introduced by Boyle et.al to produce BRL 37959.
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AlCl3 in CS2 at 00C and followed by hydrolysis to give the desired product BRL-37959{7Benzoyl- 5-chloro-2,3-dihydrobenzo[b]furan-3-carboxylic acid (5)} and of 34% in yield.
They did not able to benzoylate 3 and thus one step was increased. The overall yield of
the synthesis was only < 5%.

Scheme 2. Second Method developed by Boyle et.al to produce BRL -37959.
Since the compound seemed a potent NSAID, Beckham Research Laboratory(BRL)
developed the second method(scheme-2) to produce BRL-37595. The overall yield of the
process was also ≤ 5%. The most crucial step is benzoylation reaction(step-8), and yield
of the step is only 38% that reduced the overall yield. Then they developed also the third
method to (scheme-10) synthesize the compound, but yield was not improved (≤ 5%).
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Scheme 3. Third Method developed by Boyle et.al to produce BRL -37959.
2.1.2. Synthesis of Chiral BRL-37959
In 2012, Bongen, Patrick, and his co-workers synthesized chiral BRL-37959 by direct

Scheme 10. Method introduced by Bongen et.al to make chiral BRL-37959.
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Friedel-Crafts benzoylation of 5-choro benzofuran-3-ethyl ester (scheme- 12) and found
benzoylation exclusively at the Ortho-position (i.e., 33) in 30% yield. They followed
Hossain et al. to synthesize racemic 5-chlorobenzofuran-3-ethyl ester. Bongen, Patrick,
and his co-workers were not able to solve the problem, i.e., to improve the benzoylation
step. After benzoylation of (R) methyl 5-chloro-2,3-dihydrobenzo[b]furan-3-carboxylate
(14) they obtained only trace amount of (R) BRL-37959{7-Benzoyl- 5-chloro-2,3dihydrobenzo[b]furan-3-carboxylic acid (15)}.

2.2. Our Contribution.
2.2.1. Method development for the short synthesis of BRL-37959
Benzofuran is an essential building block of BRL 37959. In Dr. Hossain's lab, Matt
Dudley33 had discovered a novel, unique, one-pot procedure to synthesize various
benzofuran derivatives. We intended to follow the efficient, more cost-effective, largescale potential, selective, high yield and simple process to synthesize benzofuran and
designed a synthetic route (Scheme-11) to synthesize BRL-37959 with higher yield. First
step is the SN2 and ring closing reaction of starting material 5-chloro- salicylaldyde

Scheme11. Proposed synthesis of BRL-37959
.
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with Ethyl diazo acetate (EDA) and HBF4

at room temperature(RT) to yield Ethyl 5-

chloro-benzo[b]furan-3-carboxylate (2) in 94%33. Next, reduction209-210 of (2) with Mg at
RT in CH3OH formed Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3-carboxylate (3) in good
yield of 99%(Scheme 12).

Scheme 12. Preparation of Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) and
Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3)

In Boyle, et al. and Bongen et al. benzoylation of ethyl 5-chloro-2,3-dihydrobenzo[b]furan3-carboxylate (4) was done, and yield was 38% and 30% respectively. The major
challenging step was benzoylation upon which overall yield of the method depended. We
used up a much of time to improve the benzoylation of (Scheme-15) methyl 5-chloro-2,3
dihydrobenzo[b]furan-3-carboxylate (3). In benzoylation (step-3), we tried with Lewis Acid
catalyst AlCl3 along with different solvents and keeping AlCl3, benzoyl chloride,
temperature fixed. We obtained only 16% conversion in CH3NO2 (Table 4. entry:1).
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Scheme 13. Friedel-Craft benzoylation of 3.

Next, we decided to keep benzoyl chloride and solvent fixed but vary AlCl 3 and
temperature. Conversion is good,51% of yield in nitromethane at 80 0C (Table 5. entry
13).

Table 4. Effects of solvent.
Entry

Temperature (0C)

1
2
3
4
9

50
50
50
r.t
70

Benzoyl
Chloride
2 eq
2 eq
2 eq
2 eq
2 eq

AlCl3

Solvent

Time

% of Conversion

1.2 eq
1.2 eq
1.2 eq
1.2 eq
1.2 eq

Nitromethane
1,2-dichloroethane
Dichloromethane
Carbon disulfide
Acetonitrile

16h
3-days
3-days
3-days
3-days

16
0
2
8
0

We attempted to do Friedel-crafts benzoylation reactions without any solvent (Scheme16), but the conversion was not good at all (Table 6.). Meanwhile, we found that
researchers are using microwave radiation211 in organic synthesis for higher yield and
saving time. Generally, in most organic reactions, traditional heat transfer equipment such
as oil bath, sand bath, and the heating jacket is used to provide heat to the reaction
mixture. These heating systems are still rather slow, and temperature gradients can
develop within the sample. Additionally, local overheating can lead to product, reagent
and substrate decomposition. In compare, in microwave dielectric heating, the associate
microwave energy is initiated by the chemical reaction remotely, and direct access to the
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energy sources to the give reaction vessels is obtained. The microwave radiation
disseminates through the walls of the vessels and heats only reactants and solvents and
not the reaction vessel itself. If the device is appropriately designed, the temperature
increase will be even though the sample, which can bring about fewer by-products and
decomposition products. In pressurized systems, it is likely to fast increase the
temperature far above the general boiling point of the solvents used. So, we decided to
apply microwave radiation in our reactions. Before, we optimized AlCl3 loading (1.6 eq.)
(Table 5. entry 13). In case of microwave-assisted reaction (Scheme 17), we kept solvent
and catalyst loading fixed, varied benzoyl chloride, temperature as well as time to yield
67% conversion ((Table 7. entry 6). Next, we attempted to use Zn212 as a catalyst for
Friedel-craft benzoylation reaction (Scheme 16).

Table 5. Effects of AlCl3 and Temperature
Entry

Benzoyl
Chloride
2 eq
2 eq
2 eq
2 eq
2 eq
2 eq

AlCl3

Solvent

Time

1
2
3
4
5
6

Temperature
(0C)
67
67
67
75
67
67

1.2 eq
1.3 eq
1.4 eq
1.2 eq
1.2 eq
1.3eq

16h
24h
48h
16h
16h
16h

7

67

2 eq

1.5eq

16h

30

8

60

2 eq

1.5 eq

16h

19

9

r.t

2 eq

1.5 eq

3-days

8

10

r.t

2 eq

1.5 eq

10-days

18

11

70

2 eq

1.5 eq

12

80

2 eq

1.5 eq

Nitromethane
Nitromethane
Nitromethane
Nitromethane
Dry-Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane
Distilled
Nitromethane

% of
Conversion
No-product
No-product
No-product
No-product
6.33
19.5

13

80

2 eq

1.6 eq

94

Distilled
Nitromethane

16h

39

16h

42

16h

51

Scheme 14. Neat benzoylation reaction.
Table 6. Optimization of Neat Reaction.
Entry

Temperature (0C)

1

50

Benzoyl
Chloride
2 eq

2

70

3 eq

AlCl3

Time

1.6
eq
1.6
eq

3-days

% of
Conversion
8

3-days

9

Scheme 15. Benzoylation reaction with Microwave radiation.
Table 7. Effect of Temperature on Microwave reaction.
Entry

Temperature (0 C)

Benzoyl
Chloride

AlCl3

Time

% of
Conversion

1
2
3
4
5
6
7
8
9

75
75
75
75
75
80
90
80
100

2 eq
3 eq
4 eq
4.5 eq
5.5 eq
5.5 eq
5.5 eq
5.5 eq
5.5 eq

1.6 eq
1.6 eq
1.6 eq
1.6 eq
1.6 eq
1.6 eq
1.6 eq
1.6 eq
1.6 eq

1h
1h
1h
1h
1h
1h
1h
2h
1h

15
30
40
44
51
67
49
27
0
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but the conversion was unsatisfactory. We found that ionic liquids213 is used as an additive
to increase the catalytic activity of AlCl3 that leads to greater yield. We exploited ionic
liquid (Scheme 17) and obtained 37% conversion.

Scheme 16. Microwave -assisted benzoylation reaction with Zn catalyst.

Table 8. Zn catalyzed Microwave reaction.
Entry
1
2
3
4

Temperature (0
C)
100
140
140
140

Benzoyl
Chloride
1 eq
1 eq
10 eq
10 eq

Zn

Time

10 eq
10 eq
10 eq
10 eq

10 min
30 min
1h
1h

Scheme 17. Microwave- assisted reaction with additive.
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% of
Conversion
0
5
10
10

Table 9. Microwave reaction with additive.

Entry

Temperature (0C)

1
2
3

80
100
100

Benzoyl
Chloride
14.7 eq
14.7 eq
14.7 eq

AlCl3

BMIB

Time

5.40 eq
5.40 eq
5.40 eq

2.85 eq
3.88 eq
-

1h
1h
1h

% of
Conversion
37
15
22

Since in benzoylation reaction (Scheme 13), we obtained only 51% conversion, and
overall yield would not be high, we proposed another route (Scheme 20). We used 5chloro-2-hydroxy benzophenone as a starting material to avoid benzoylation (20). We did
Reimer-Tiemann reaction (Scheme 19) to convert 19 to 7-benzoyl-5-chlorosalicylaldehyde (20), but unfortunately, no product was formed.

Scheme 18. Proposed synthesis of BRL-37959
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Scheme 19. Reimer-Tiemann reaction of 5-chloro-2-hydroxy benzophenone (20).
Table10. Reimer-Tiemann reaction.
Entry

NaOH

CHCl3

Time

1

Temperature
(0 C)
110

7.5 eq

2 eq

5 min

% of
Conversion
0

2
3
4
5
6
7

110
120
170
170
90
120

7.5 eq
7.5 eq
10 eq
10 eq
10 eq
10 eq

2 eq
6 eq
30 eq
30 eq
30 eq
30 eq

10 min
5 min
5 min
10
1h
4h

0
0
0
0
0
0

We continuously persuaded to search a suitable catalyst for increasing conversion of
benzoylation step and found that J.R. Desmur and his co-workers used Bi(OTf)3 catalyst
in Friedel-Craft benzoylation reaction as well as obtained 80-98% yield214. Next, we
decided to use the super catalyst in our benzoylation reaction. First, we applied the great
catalyst in microwave irradiation reaction (Scheme 20). We kept benzoyl chloride, catalyst
Bi(OTf)3, time fixed and varied temperature and achieved excellent yield of 77% (Table
11, entry 3)
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Scheme 20. Microwave- assisted reaction with Bi catalyst
Table 11. Effect of Temperature on Bi(OTf)3 catalyzed Microwave
Benzoylation reaction
Entry Temperature(0C)
1
2
3

100
120
140

Benzoyl Bi(OTf)3
Time
Chloride
2.2 eq
0.1 eq
30 min
2.2 eq
0.1 eq
30 min
2.2 eq
0.1 eq 30 min

% of
Conversion
55
67
87

% of
Yield
77

Being inspired by the super activity of the catalyst, we planned to utilize Bi(OTf)3 in
traditional Friedel-Craft benzoylation reaction (Scheme 21). We optimized benzoyl
chloride, catalyst loading, and temperature to obtain a higher yield of 70%(Table: 12,
entry 3)

Scheme 21. Conventional benzoylation reaction with Bi catalyst.
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Table 12. Effect of Catalyst loading and Temperature
Entry

Temperature (0C)

1
2
3
4

90
100
90
90

Benzoyl
Chloride
0.5 eq
0.5 eq
2.3 eq
2.3 eq

Bi(OTf)3

Time

0.1 eq
0.1 eq
0.2 eq
0.2 eq

3 days
3 days
3 days
3 days

% of
Conversion
64
59
87
90

% of Yield
70
70

Scheme 22. Hydrolysis of Methyl-7-Benzoyl -5-Chloro-2,3-dihydrobenzo [b] furan-3carboxylate (15)
Next, hydrolysis of 15 with NaOH in methanol and water at RT (Scheme 22) formed final
product BRL-37959 (5-chloro-7-benzoyl-2,3-dihdrobenzo[b]furan-3-carboxyllic acid) (5)
in the great yield of 99%.

Total Synthesis of BRL-37959:
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2.2.2. Synthesis of analogs of BRL-37959

Now, we developed the methodology of benzoylation reaction; we planned to apply the
developed method to synthesize some analogs of BRL-37959. First, we intended to make
Fluoro-analog of BRL-37959 (26) and followed our established synthetic route (Scheme
25). The step:1 is the SN2 and ring closing reaction33 of starting material 5-Fluoro-

.

Scheme 23. Proposed synthesis of 7-Benzoyl- 5-Fluoro-2,3-dihydrobenzo[b]furan-3carboxylic acid (26)

salicylaldyde with Ethyl diazo acetate(EDA) and HBF4 at room temperature (RT) to yield
Ethyl 5-Fluoro-benzo[b]furan-3-carboxylate (23) in 74%. Subsequently, reduction209-210

Scheme 24. Synthesis of Methyl 5-fluoro-2,3-dihydrobenzo[b]furan-3-carboxylate (24)
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of (23) with Mg at RT in CH3OH formed Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3carboxylate (24) in the good yield of 82% (Scheme 24). In microwave-assisted
benzoylation reaction (Scheme 25) of (24) hold catalyst loading, benzoyl chloride fixed
and changed temperature as well as time to yield 78% (Table 13, entry 3). After that, we
focused on typical benzoylation (Scheme 26) of 24. We fixed temperature, time and
altered catalyst as well as benzoyl chloride to get 50% in yield. (Table 14, entry 3).

Scheme 25. Microwave- assisted reaction with Bi catalyst.
Table13. Effect of Temperature on Bi(OTf)3 catalyzed Microwave
benzoylation reaction
Entry

Temperature (0C)

1
2
3
4

100
120
140
150

Benzoyl
Chloride
2.2 eq
2.2 eq
2.2 eq
2.2 eq

Bi(OTf)3

Time

% of Yield

0.1 eq
0.1 eq
0.1 eq
0.1 eq

20 min
30 min
20 min
30 min

45
56
78
63

Scheme 26. Conventional benzoylation reaction with Bi catalyst
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Table14. Effect of catalyst loading on traditional benzoylation reaction.
Entry Temperature(0C)
1
2
3

90
90
90

Benzoyl Bi(OTf)3
Chloride
2.3 eq
0.05 eq
2.3 eq
0.1 eq
2.3 eq
0.2 eq

Time
3 days
3 days
3 days

% of
Yield
30
50
50

Scheme 27. Hydrolysis of Methyl-7-Benzoyl -5-Fluoro-2,3-dihydrobenzo
[b] furan-3- carboxylate (26).

Total Synthesis of 5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo
[b] furan-3- carboxylic acid (26)
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Next, we decided to synthesize methyl-analog of BRL-37959 (5-Methyl-7-Benzoyl- 2,3dihydrobenzo[b]furan-3-carboxylic acid (31) by following our developed synthetic route
(Scheme 28).

Scheme 28. Proposed synthesis of 7-Benzoyl- 5-Methyl-2,3-dihydrobenzo[b]furan-3carboxylic acid (31).
The first step is the SN2 and ring closing reaction of starting material 5-Methylsalicylaldyde with Ethyl diazo acetate(EDA) and HBF4 at room temperature (RT) to yield
Ethyl 5-Methyl-benzo[b]furan-3-carboxylate (28) in 81%33. After that, reduction209-210 of
(28) with Mg at RT in CH3OH formed Methyl 5-Fluro-2,3-dihdrobenzo[b]furan-3carboxylate (29) in a good yield of 91% (Scheme 29). We pursued our optimized

Scheme 29. Synthesis of Methyl 5-methyl-2,3-dihdrobenzo[b]furan-3carboxylate (29)
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microwave benzoylation reaction (Scheme 30) and formed 30 to yield in 72%(Table15,
entry 3). Consequently, we augmented traditional Friedel-craft benzoylation (scheme
30) and achieved 77 % in yield (Table 16, entry 3).

Scheme 30. Microwave -assisted reaction with Bi catalyst.

Table 15. Effect of temperature on microwave -mediated benzoylation reaction.

Entry
1
2
3

Temperature(0C)
100
120
140

Benzoyl
Chloride
2.2 eq
2.2 eq
2.2 eq

Bi(OTf)3

Time

% of Yield

0.1 eq
0.1 eq
0.1 eq

30 min
30 min
30 min

45
60
72

Scheme 31. Conventional benzoylation reaction with Bi catalyst
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Table 16. Optimization of traditional benzoylation reaction with Bi(OTf)3

Entry

Temperature (0C)

1
2
3
4

90
100
90
90

Benzoyl
Chloride
2.3 eq
2.3 eq
2.3 eq
2.3 eq

Bi(OTf)3

Time

% of Yield

0.1 eq
0.1 eq
0.15 eq
0.2 eq

3 days
3 days
3 days
3 days

59
63
67
77

Scheme 32. Hydrolysis of Methyl-7-Benzoyl -5-Methyl-2,3-dihydrobenzo [b] furan-3carboxylate (30)

Total Synthesis of 7-Benzoyl -5-Methyl-2,3-dihydrobenzo [b] furan-3carboxylic acid (31)
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Afterwards, we designed to prepare methoxy analog of BRL-37959(7-Benzoyl- 5Methoxy-2,3-dihydrobenzo[b]furan-3-carboxylic acid) (36) and stuck to our improved
synthetic route (Scheme 33). The first step is the SN2 and ring closing reaction of starting

Scheme 33. Proposed synthesis of 7-Benzoyl- 5-Methoxy-2,3-dihydrobenzo[b]furan3-carboxylic acid (36).

material 5-Methoxy- salicylaldyde with Ethyl diazo acetate(EDA) and HBF 4 at room
temperature (RT) to yield Ethyl 5-Methoxy-benzo[b]furan-3-carboxylate (33) in 81%33.
Next, reduction209-210 of (33) with Mg at RT in CH3OH formed Methyl 5-Methoxy-2,3107

dihdrobenzo[b]furan-3-carboxylate (34) in a good yield of 91%(Scheme-34). Microwaveassisted benzoylation reaction (Scheme 35) was carried out with noble catalyst Bi(OTf)3
to yield 50%(Table 17, entry 4) Subsequently, we kept on our optimized standard Friedelcraft benzoylation (Scheme-36) and obtained 65% in yield (Table 18, entry 2).

Scheme 34. Reduction of Ethyl 5-methyl-benzo[b]furan-3 carboxylate (33)

Scheme 35. Microwave -assisted reaction with Bi catalyst.
Table 17. Effect of temperature on microwave benzoylation reaction.
Entry
1
2
3
4
5

Temperature
(0C)
100
120
120
140
140

Benzoyl Bi(OTf)3
Chloride
2.2 eq
0.1 eq
2.2 eq
0.1 eq
2.2 eq
0.1 eq
2.2 eq
0.1 eq
2.2 eq
0.1 eq
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Time

% of Yield

30 min
35 min
30 min
30min
35 min

31
36
40
50
42

Scheme 36. Traditional benzoylation reaction with Bi catalyst

Table18. Effect of catalyst loading on conventional benzoylation reaction.
Entry

Temperature (0C)

1
2

90
90

Benzoyl
Chloride
2.3 eq
2.3 eq

Bi(OTf)3

Time

% of Yield

0.1 eq
0.2 eq

3 days
3 days

50
65

Scheme 37. Hydrolysis of Methyl-7-Benzoyl -5-Methoxy-2,3- dihydrobenzo [b] furan3- carboxylate (36)
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Total Synthesis of 5-Methoxy 7-Benzoyl --2,3-dihydrobenzo [b] furan-3carboxylic acid (36).

We performed Molecular Modeling Study of BRL-37959, and p-hydroxy analog of BRL37959 {7-(4-hydroxy) Benzoyl- 5-Chloro-2,3-dihydrobenzo[b]furan-3-carboxylic acid} and
found that both bind with the COX-2 enzyme (Figure- 18,19), but later bind tightly to the
enzyme. Because of the hydroxyl group in p-hydroxy analog of BRL-37959 forms
hydrogen bond with amino acid of the COX-2 enzyme. Now, we planned to make more
analogs by placing different substituents in para-position of benzoyl group in BRL-37959.
First,

we

decided

to

synthesize

7-(4-tri-fluromethyl)

Benzoyl-

5-Chloro-2,3-

dihydrobenzo[b]furan-3-carboxylic acid (38). We followed our developed synthetic
method (Scheme 38) and in benzoylation reaction (Scheme-39) p- trifluoromethyl benzoyl
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Scheme 38. Proposed synthesis of 7-(4-tri-fluromethyl) Benzoyl- 5-Chloro-2,3dihydrobenzo[b]furan-3-carboxylic acid (38).

Scheme 39. Microwave -assisted reaction with Bi catalyst
Table 19. Effect of benzoylation reaction with Bi(OTf)3
Entry
1
2
3
4
5

Temperature
(0C)
140
140
120
120
120

7-(4-tri-fluromethyl)
benzoyl Chloride
1 eq
8.6 eq
7.5 eq
8.6 eq
4 eq
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Bi(OTf)3

Time

0.1 eq
0.1 eq
0.1 eq
0.1 eq
0.1 eq

20 min
30 min
30 min
1h
1h

% of
Yield
22
76
70
79
51

chloride was treated with 3 and super catalyst Bi(OTf)3 to produce 7-(4-trifluromethyl)
Benzoyl -5-Chloro-2,3- dihydro benzo [b] furan-3- carboxylate (37) 79% in yield Table 19,
entry 4). Next, hydrolysis of 37 with NaOH in methanol and water at RT (Scheme 40)
formed the final product, 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3- dihydro benzo [b]
furan-3-carboxylic acid) (38) in the high yield of 94%.

Scheme 40. Hydrolysis of 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3dihydrobenzo [b] furan-3- carboxylate (38)

Total Synthesis of 7-(4-trifluromethyl) Benzoyl -5-Chloro-2,3-dihydro
benzo[b] furan-3- carboxylic acid (38).
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After that, we worked out to make of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydro benzo
[b]furan-3-carboxylic acid (40) (Scheme 41). We retained catalyst loading, as fixed, varied
temperature, and benzoyl chloride as well as time in benzoylation (Scheme 42) to yield
of 48% (Table 18, entry 4). Next, the final product, 7-(4-fluro) benzoyl -5-Chloro-2,3dihydro benzo [b] furan-3-carboxylic acid (40) formed (yield 99%) after hydrolysis of 39
with NaOH in methanol and water at RT (Scheme-43).

Scheme 41. Proposed synthesis of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydro
benzo[b]furan-3-carboxylic acid (40).

Scheme 42. Microwave assisted reaction with Bi catalyst.
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Table 20. Effect of temperature benzoylation reaction.
Entry
1
2
3
4

Temperature
(0C)
140
140
100
120

4-Fluro Benzoyl

Bi(OTf)3

Time

Chloride
8.5 eq
10.8 eq
10.8 eq
10.8 eq

0.1 eq
0.1 eq
0.1 eq
0.1 eq

20 min
1h
1h
1h

% of
Yield
38
48
45
48

Scheme 43. Hydrolysis of 7-(4-fluro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan-3carboxylate (40).

Thus, Total Synthesis of 7-(4-fluro) Benzoyl -5-Chloro-2,3dihydrobenzo[b] furan-3- carboxylic acid (41)
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Later, we planned to synthesize 7-(4-chloro) Benzoyl- 5-Chloro-2,3-dihydro benzo[b]
furan-3-carboxylic acid (42) by following our established synthetic route (Scheme 44).
We kept benzoyl chloride and time as fixed, but altered catalyst loading and temperature
in benzoylation reaction (Scheme 45) to form 41 yield in 70% (Table19. entry 6).
Subsequent, hydrolysis (Scheme 46) we obtained target compound with 99 % in yield.
Scheme 44. Proposed synthesis of 7-(4-Chloro) Benzoyl- 5-Chloro-2,3dihydrobenzo b] furan-3-carboxylic acid (42).

Scheme 45. Microwave assisted reaction with Bi catalyst.
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Table 21. Effect of catalyst loading on benzoylation reaction.
Entry
1
2
3
4
5
6

Temperature (0C)
100
120
140
120
120
120

Benzoyl
Chloride
2.2 eq
2.2 eq
2.2 eq
2.2 eq
2.2 eq
2.2 eq

Bi(OTf)3

Time

% of Yield

0.2 eq
0.2 eq
0.2 eq
0.3 eq
0.3 eq
0.3 eq

1h
1h
1h
1h
1h
1h

41
47
49
51
69
70

Scheme 46. Hydrolysis of 7-(4-Chloro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan3- carboxylate (41).
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Total Synthesis of 7-(4-chloro) Benzoyl -5-Chloro-2,3- dihydrobenzo[b]
furan-3- carboxylic acid (42)

Next, we decided to make 7-(4-Notro) Benzoyl- 5-Chloro-2,3-dihydro benzo[b] furan-3carboxylic acid (44). We did benzoylation reaction by pursuing our established synthetic
route (Scheme 47) to form 43 (Scheme 48) yield in 56% (Table:20, entry 4).

Scheme 47. Proposed synthesis of 7-(4-Nitro) Benzoyl- 5-Chloro-2,3- dihydrobenzo
[b]furan -3-carboxylic acid (44).
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Consequent, hydrolysis (Scheme 49) we found final product 45 with 95 % in yield.

Scheme 48. Microwave-assisted reaction with Bi catalyst

Table 22. Optimization of benzoylation reaction with Bi(OTf)3
Entry
1
2
3
4

Temperature (0C)
80
90
100
120

Benzoyl
Chloride
2.2 eq
2.2 eq
2.2 eq
2.2 eq

Bi(OTf)3

Time

% of Yield

0.2 eq
0.2 eq
0.2 eq
0.2 eq

1h
1h
1h
1h

43
46
53
56

Scheme-49. Hydrolysis of 7-(4-Nitro) Benzoyl -5-Chloro-2,3- dihydrobenzo [b] furan3- carboxylate (43)
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Thus, Total Synthesis of 7-(4-Nitro) Benzoyl -5-Chloro-2,3dihydrobenzo[b] furan-3- carboxylic acid (44)

Afterwards, we designed to the synthesis of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3dihydrobenzo[b]furan-3-carboxyllate (45) and stuck to our improved synthetic route

Scheme 50. Proposed synthesis of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3dihydrobenzo[b]furan-3-carboxyllate (45).
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(Scheme 50). Microwave-assisted benzoylation reaction (Scheme-51) was carried out
with great catalyst Bi(OTf)3 to yield 48%(Table:21, entry 4).

Scheme 51. Microwave assisted reaction with Bi catalyst
Table 23. Effect of Temperature on benzoylation reaction with Bi(OTf)3.
Entry

Temperature (0C)

1
2
3
4

100
100
120
140

7-(4-Methyl thiol)
Benzoyl Chloride
1 eq
2.2 eq
2.2 eq
2.2 eq

Bi(OTf)3

Time

% of Yield

0.2 eq
0.2 eq
0.2 eq
0.2 eq

1h
1h
1h
1h

40
45
48
54

Next, we planned to synthesis of 7-(4-hydroxy) Benzoyl- 5-Chloro-2,3-dihydro
benzo[b]furan-3-carboxyllate (47) and followed to our developed synthetic route (Scheme
51). Microwave-assisted benzoylation reaction (Scheme 56) was carried out with noble

120

Scheme 52. Proposed synthesis of 7-(4-hydroxy) Benzoyl- 5-Chloro-2,3dihydrobenzo[b]furan-3-carboxyllate (47).

catalyst Bi(OTf)3, but unfortunately, the reaction did not happen.

Scheme-53. Microwave assisted reaction with Bi catalyst

Afterwards, we decided to synthesis of 7-(4-Methyoxy) Benzoyl- 5-Chloro-2,3dihydrobenzo[b]furan-3-carboxyllate (45) and followed our improved synthetic route
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Scheme 54. Proposed synthesis of 7-(4-Methoxy) Benzoyl- 5-Chloro-2,3- dihydrobenzo
[b]furan -3-carboxylic acid (50).
(Scheme-54). Microwave-assisted benzoylation reaction (Scheme-55) was carried out
with great catalyst Bi(OTf)3 to yield 45%(Table:22, entry 3).

Scheme-55. Microwave assisted reaction with Bi catalyst.
Table 24. Effect of Temperature on benzoylation reaction with Bi(OTf)3.
Entry

Temperature (0C)

1
2
3
4

90
100
120
140

7-(4-Methoxy)
Benzoyl Chloride
1 eq
2.2 eq
2.2 eq
2.2 eq

122

Bi(OTf)3

Time

% of Yield

0.2 eq
0.2 eq
0.2 eq
0.2 eq

1h
1h
1h
1h

38
44
45
42

2.3. Enzyme Inhibition studies.
2.3.1. Enzymes
The expression and purification of murine COX-2 (mCOX-2) from insect cells and of ovine
COX-1 (oCOX-1) from ram seminal vesicles were done by following published
methods218-220 All activity or inhibition studies were performed in 100 mM Tris-HCl buffer
containing 500 µM phenol. Inhibitors were dissolved in dimethyl sulfoxide. Reaction
mixtures contained hematin-reconstituted proteins at final enzyme concentrations
adjusted to give approximately 30-35% substrate consumption (mCOX-2 = 77 nM, oCOX1 = 22.5 nM). Fig-18 shows that BRL-37959 is a selective COX-1 inhibitor with IC50 value
of 245nM.

Figure-40: Inhibition of puriﬁed Wt mCOX-2 and oCOX-1, by BRL-37959.

123

2.4. Cellular Assays (Proliferation Assay)
The anti-proliferative activities of the BRL-37959 was verified against colon, breast,
ovarian and prostate cancer cell lines in an MTT using the Indomethacin as a positive
control. The MTT assay is a colorimetric assay for measuring cell viability221. NAD(P)Hdependent cellular oxidoreductase enzymes indicate the number of viable cells present.
These enzymes can reduce the tetrazolium dye MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. The
absorbance of this colored solution can be quantified by measuring at a certain
wavelength (normally between 500 to 600 nm) by a spectrophotometer. The degree of
light absorption depends on the solvent and how many living cells reduced MTT (yellow)
to formazan (purple)222.

% Anti-Proloferation of Cell by compound
60%
50%
40%
30%
20%
10%
0%
COL0205(Colon)
SKOV-3(Ovarian) MDAMB23(Breast)
80 µM
100 µM
120 µM
140 µM

Figure 41: Proliferation Assay of BRL-37959.
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DV145(Prostate)

3. General Methods and Experimental
3.1. General considerations
All reactions were performed under a nitrogen atmosphere in oven-dried glassware with
magnetic stirring. Air and moisture-sensitive liquids and solutions were transferred via an
oven-dried, stainless steel syringe and were introduced into the reaction vessel through
rubber septa. CH2Cl2 was distilled from calcium hydride. Other solvents used were
distilled from sodium-benzophenone ketyl. Freshly distilled solvents were then degassed
for Pd-catalyzed reactions by freeze-pump-thaw techniques under vacuum. Previously
reported compounds were identified by 1H NMR (nuclear magnetic resonance) spectra.
All new compounds were characterized by additional 13C NMR and high-resolution mass
spectroscopy. Analytical thin layer chromatography (TLC) was performed on silica gel
plates (Merck 60F254) visualized either with a UV lamp (254 nm) or by using an iodine
chamber. Flash chromatography was performed using 40-60 µm silica gel (Silicycle).
The eluent employed for flash chromatography is reported as volume/volume ratios.
Organic extracts were dried over anhydrous Na2SO4. The 1H and 13C NMR Spectra were
performed on a Bruker NMR at 300 and 75 MHz, or 500 and 125 MHz respectively. The1H
NMR spectral data are reported as follows: chemical shift (δ) in parts per million (ppm)
from tetramethylsilane as an internal standard (CDCl3 δ7.26 ppm), multiplicity (s = singlet,
d = doublet, t = triplet, q = quartet, m = multiplet), intégration. 13C data were reported as
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follows: chemical shifts (δ) are reported in parts per million (ppm) from tetramethylsilane
with the solvent as an internal standard (CDCl3 δ77.16 ppm). HPCL analysis was115
performed using a Waters 1500 Series HPLC equipped with a Regis Technologies Pirkle.
High-resolution mass spectra were done in the MS Shimadzu Laboratory for Advanced
and Applied Analytical Chemistry at the University of Wisconsin –Milwaukee.

3.2. Experimental Procedures
3.2.1.1. Preparation of Ethyl 5-chloro-benzo[b]furan-3-carboxylate33 (2)
5-chlorosalicylaldehyde (1g, 6.39 mmol) was added to a 100 mL 3-neck round bottom
flask fitted with an addition funnel along with 2 mL dichloromethane (DCM). The mixture
was stirred at room temperature to make a slurry. After this,0.1mL HBF4·OEt2 (0.734
mmol) was added by a syringe directly to the solution and it was stirred for 15 min for
protonation of the aldehyde. 2 mL ethyl diazoacetate(EDA) (10.41 mmol) was added to
the addition funnel along with 1mL DCM. The EDA solution was added dropwise over a
period of 5-6 hours. The dark yellow colored solution was allowed to stir for 12 hrs. under
a nitrogen atmosphere. After that, the addition funnel was removed and the reaction
mixture was concentrated under rotary evaporation to remove free EDA. Then 0.4 mL of
99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask was
placed in an ice-bath and 10 min later the solution was diluted with 2 ml of DCM. The
acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The
reaction mixture was extracted by DCM. The organic layers were combined and dried
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over anhydrous Na2SO4 and the solvent was removed by rotovaporation as well as
yellowish white solid crude product obtained.
The crude product was dissolved in anhydrous ethanol and 0.183 g NaOH was added.
The solution was stirred at 380C for 1h. After this, the solution cooled down to room
temperature and deionized water was added dropwise until no precipitate formed. The
round bottom flask was placed in an ice-bath for 5-10 minutes and then filtered on a
Buchner funnel. The off white solid material was allowed to dry on the Buchner Filter for
1 hr. After that, the material was sublimed under high vacuum and clear white crystals of
product (99% purity) was obtained.
1H

NMR (300 MHz, CDCl3): δ 8.24(s, 1H), 8.00 (d, 1H), 7.42 (d, 1H), 7.29 (dd, 1H),4.41

(q, 2H), 1.43 (t, 3H).
The analytical data matched with that of previously reported33 data.

3.2.1.1a. Preparation of Ethyl 5-fluroro-benzo[b]furan-3-carboxylate33 (23)
5-Fluorosalicylaldehyde (1g, 7.14 mmol) was added to a 100 mL 3-neck round bottom
flask fitted with an addition funnel along with 6 mL dichloromethane (DCM). The mixture
was stirred at r.t. to make a slurry. After this, 0.1mL HBF4·OEt2 (0.735 mmol) was added
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde.
Then, 1.01 mL ethyl diazoacetate(EDA) (9.55 mmol) was added to the addition funnel
along with 1mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs.
The dark yellow colored solution was allowed to stir for 12 hrs. under a nitrogen
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atmosphere. After that, the addition funnel was removed and the reaction mixture was
concentrated on a rotary evaporation to remove the remaining EDA. Then 0.5 mL of
99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask was
placed in an ice-bath and 10 min later the solution was diluted with 2 mL of DCM. The
acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The
reaction mixture was then extracted by DCM. The organic layers were combined and
dried over anhydrous Na2SO4 and the solvent was removed by rotovaporation and a
yellowish white colored solid crude product was obtained.
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The
solution was stirred at 380C for 1h. After this, the solution was cooled down to r.t. and
deionized water was added dropwise until no precipitate formed. The round bottom flask
was placed in ice-bath for 5-10 min. and the mixture filtered on a Buchner funnel. The off
white solid material was allowed to dry on the Buchner filter for 1 hr. After that, the material
was sublimed under high vacuum and clear white crystals of product (99% purity) was
obtained. The analytical data matched with previously reported33 data.

3.2.1.1b. Preparation of Methyl 5-methyl-benzo[b]furan-3-carboxylate33 (28)
5-methylsalicylaldehyde (1g, 7.34 mmol) was added to a 100 mL 3-neck round bottom
flask fitted with an addition funnel along with 4 mL dichloromethane (DCM). The mixture
was stirred at r.t. to make a slurry. After this,0.1mL HBF4·OEt2 (0.734 mmol) was added
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde.
Then,1.07 mL of Ethyl diazoacetate(EDA) (10.12 mmol) was added to the addition funnel
along with 2 mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs.
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The dark yellow colored solution was allowed to stir for 12 hrs. under a nitrogen
atmosphere. After that, the addition funnel was removed and the reaction mixture was
concentrated under a rotary evaporatory to remove the remaining EDA. After this,0.4 mL
of 99.99% H2SO4 was added dropwise to the viscous solution. The round bottom flask
was placed in an ice-bath and 10 min later the solution was diluted with 2 mL of DCM.
The acidic reaction mixture was neutralized by adding saturated of NaHCO3 solution. The
reaction mixture was extracted by DCM. The organic layers were combined and dried
over anhydrous Na2SO4 and the solvent was removed by rotary evaporation and a
yellowish white solid crude product was obtained.
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The
solution was stirred at 380C for 1h. After this, the solution was cooled to r.t. and deionized
water was added dropwise until no precipitate formed. The round bottom flask was placed
in an ice-bath for 5-10 min. and filtered on a Buchner funnel. The off white solid material
allowed to dry on the Buchner filter for 1 hr. After that, the material was sublimed under
high vacuum and clear white crystals of product (99% purity) was obtained. The analytical
data matched with previously reported33 data.

3.2.1.1c. Preparation of Ethyl 5-Methoxy-benzo[b]furan-3-carboxylate33 (33)

5-methoxysalicylaldehyde (1g, 6.57 mmol) was added to a 100 mL 3-neck round bottom
flask fitted with an addition funnel along with 5 mL dichloromethane (DCM). The mixture
was stirred at r.t. to make a slurry. After this, 0.1mL HBF4·OEt2 (0.734 mmol) was added
by a syringe directly to the solution and stirred for 15 min for protonation of the aldehyde.
0.85 mL Ethyl diazoacetate(EDA) (7.80 mmol) was added to the addition funnel along
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with 1mL DCM. The EDA solution was added dropwise over a period of 5-6 hrs. The dark
yellow colored solution was allowed to stir for 12 hrs under a nitrogen atmosphere. After
that, the addition funnel was removed and the reaction mixture was concentrated under
a rotary evaporatory to remove the remaining EDA. After this,0.4 mL of 99.99% H2SO4
was added dropwise to the viscous solution. The round bottom flask was placed in an icebath and 10 min later the solution was diluted with 2 mL of DCM. The acidic reaction
mixture was neutralized by adding saturated of NaHCO3 solution. The reaction mixture
was extracted by DCM. The organic layers were combined and dried over anhydrous
Na2SO4 and the solvent was removed by rotary evaporation and a yellowish white solid
crude product was obtained.
The crude product was dissolved in anhydrous ethanol and 0.2 g NaOH was added. The
solution was stirred at 380C for 1h. After this, the solution was cooled to r.t. and deionized
water was added dropwise until no precipitate formed. The round bottom flask was placed
in an ice-bath for 5-10 min. and filtered on a Buchner funnel. The off white solid material
allowed to dry on the Buchner filter for 1 hr. After that, the material was sublimed under
high vacuum and clear white crystals of product (99% purity) was obtained. The analytical
data matched with previously reported33 data.

3.2.1.2. Preparation of Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3carboxylate (3)

Ethyl 5-chloro-benzo[b]furan-3-carboxylate (2) (1g, 4.45mmol) was dissolved in
methanol(35mL) followed by addition of magnesium powder of ~300 mesh (1.2g,0.05
mol). The reaction mixture was stirred for 3 days under a nitrogen atmosphere at r.t. After
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that, the reaction mixture was poured to 35 mL of deionized water to quench the reaction
and ash colored solid material formed. Then, the Erlenmeyer flask containing the reaction
mixture was placed in an ice bath and 5M HCl was added dropwise until P H would be
1.0. The solution was extracted with diethyl ether. The organic layers were combined,
washed with brine and dried over anhydrous Na2SO4 and the solvent was removed by
rotary evaporation as well as pale yellow oily product obtained (1.42g, 99% yield).
1H

NMR (300 MHz, CDCl3): δ 7,41(d, J=2Hz,1H), 7.17 (dd, J=8& 2Hz 1H), 6.67 (d,

J=8Hz,1H), 4.99 -4.37 (m, 3H), 3.82(s,3H).
3.2.1. 2.a. Methyl 5-Fluoro 2,3-dihdro benzo[b]furan-3-carboxylate (24).
Ethyl 5-fluoro-benzo[b]furan-3-carboxylate (2) (1.2g, 5.71mmol) was dissolved in
methanol (20 mL) followed by addition of magnesium powder of ~300 mesh (1.44g,0.06
mol). After that, the reaction mixture was allowed to stir for 3 days under a nitrogen
atmosphere at r.t. Then the reaction mixture was poured to 20 mL of deionized water to
quench the reaction and ash colored solid material was formed. After that, the Erlenmeyer
flask containing the reaction mixture was placed in an ice bath and 5M HCl was added
dropwise until PH would be 1.0. Then, the solution was extracted with diethyl ether. The
organic layers were combined, washed with brine and dried over anhydrous Na2SO4 and
the solvent was removed by rotary evaporation and pale yellow oily product was obtained
(0.90g, 81% yield). The analytical data matched with previously reported33data.
3.2.1. 2.b. Methyl- 5-Methyl -2,3-dihdro benzo[b]furan-3-carboxylate (29)
Ethyl 5-methyl-benzo[b]furan-3-carboxylate (2) (1g, 4.85mmol) was dissolved in
methanol (35mL) followed by addition of magnesium powder of ~300 mesh (1.1g,0.05
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mol). Then, the reaction mixture was allowed to stir for 3 days under a nitrogen
atmosphere at r.t. After this, reaction mixture was poured to 35 mL of deionized water to
quench the reaction and ash colored solid material formed. Then, the Erlenmeyer flask
containing the reaction mixture was placed in an ice bath and 5M HCl was added
dropwise until PH would be 1.0. After that, the solution was extracted with diethyl ether.
Then, the organic layers were combined, washed with brine and dried over anhydrous
Na2SO4 and the solvent was removed by rotary evaporation and yellow oily product was
obtained (0.85g, 91% yield.
The analytical data matched with previously reported33 data.

3.2.1. 2.c. Methyl- 5-Methoxy -2,3-dihdro benzo[b]furan-3-carboxylate (34).
Methyl 5-methoxy-benzo[b]furan-3-carboxylate (2) (1g, 4.45mmol) was dissolved in
methanol (35mL) followed by addition of magnesium powder of ~300 mesh (1.2g,0.058
mol). Then, the reaction mixture was allowed to stir for 3 days under nitrogen a
atmosphere at r.t. After this, the reaction mixture was poured to 35 mL of deionized water
to quench the reaction and ash colored solid material formed. Then, the Erlenmeyer flask
containing the reaction mixture was placed in an ice bath and 5M HCl was added
dropwise until PH would be 1.0. The solution was extracted with diethyl ether. After that,
the organic layers were combined, washed with brine and dried over anhydrous Na2SO4
and the solvent was removed by rotovaporation as well as pale yellow oily product
obtained (0.85g, 92% yield.
Analytical data matched with previously reported33data.
132

3.2.1.3. Method A: Synthesis of Methyl-7-benzoyl 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (15)

AlCl3 (1g.,7.45 mmol) was added to a 100 mL 3-neck round bottom flask fitted with
condenser and septum connected to a nitrogen line. 10 mL nitromethane was charged
into the flask. Benzoyl chloride (1 mL,8.79 mmol) was added by a syringe followed by the
addition of solution of Mthyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate
(1g.,4.2 mmol, in 10 mL nitromethane). Then, the reaction mixture was heated to 670 C
with constant stirring for 3 days. Excess nitromethane was removed by rotary evaporator.
After that, the round bottom flask was placed in an ice-bath and the dark oil residue was
quenched with concentrated HCl (7 mL) .15 ml of H2O was added to the flask and
aqueous layer was removed. Then, 15 ml of H2O was added to the flask and extracted
with 30 mL of CH2Cl2. The organic layers were combined and dried over anhydrous
Na2SO4 and the solvent was removed by rotovaporation as well as black crude product
was obtained. 1NMR indicated that roughly 51% of the mixture contained Mthyl-7-benzoyl
5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15).
1H

NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t,

J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H),
3.86(s,3H).
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3.2.1.4 Method B: Microwave-assisted synthesis of Methyl-7-benzoyl 5chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15)

AlCl3 (144 mg., 1.0 mmol) was added to a 10-mL pressurized tube fitted with a magnet
bar and septum connected to a nitrogen line. Then, benzoyl chloride (0.4 mL,3.75 mmol)
was added by a syringe followed by the addition of 1mL of nitromethane. After this, the
reaction was stirred for 20 min and catalyst was dissolved. Then, the solution of Mthyl-7benzoyl 5-chloro-2,3-dihdro benzo [b]furan-3- carboxylate (100 mg.,0.47 mmol, in 1 mL
nitromethane) was added to the tube and quickly septum was removed as well as sealed
with the high -pressure tolerance septum. After that, the glass tube was placed into a
CEM microwave at the temperature 800 C, pressure 40 PSI with high steering for 1h. The
reaction mixture could cool to the room temperature in the MW oven. After cooling, the
mixture was transferred to the Elamnary flask by CH2Cl2. The flask was placed in an icebath and the dark oil residue was quenched with concentrated HCl (3 mL). 5 mL of CH2Cl2
and 5 mL of H2O was added to the flask and aqueous layer was removed. Then, 15 ml of
H2O was added to the flask and extracted with 30 mL of CH2Cl2. The organic layers were
combined and dried over anhydrous Na2SO4 and the solvent was removed by
rotovaporation as well as black crude product obtained. 1NMR indicated that roughly 67%
of

the

mixture

contained

Mthyl-7-benzoyl

5-chloro-2,3-dihdrobenzo[b]furan-3-

carboxylate (15).
1H

NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t,

J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H),
3.86(s,3H).
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3.2.1.5 Microwave-assisted synthesis of Methyl-7-benzoyl 5-chloro-2,3dihdrobenzo [b]furan-3- carboxylate (15) using Zn and Zn with BMIB (ionic liquid).
We followed the same procedure of 3.2.1.4. to synthesize Methyl-7-benzoyl 5-chloro2,3-dihdrobenzo[b]furan-3- carboxylate (15).
3.2.1.6 Method C: Microwave-assisted synthesis of Methyl-7-benzoyl 5-chloro-2,3dihydro benzo [b] furan-3- carboxylate (15) using Bi(OTf)3 as a catalyst.
Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) was
added to a 10mL pressurized glass tube fitted with a septum connected to a nitrogen line.
Next, Bi(OTf)3 (60 mg,0.046 mmol) was added to the tube followed by the addition of
1.5mL of nitrobenzene. Benzoyl chloride (0.08 mL,0.01 mmol) was added by a syringe
and quickly septum was removed as well as sealed with the High -pressure tolerance
septum. The microtube was placed in the microwave for 1 hour to react at 80 0 C,
temperature, 40 PSI pressure with high steering. The reaction mixture was transferred to
the Elamnary flask. The dark oil residue was quenched with 15 ml of H2O and 10 ml
CH2Cl2 was added to the flask. Next the solution was passed through the silica plug. The
filtrate was extracted with 30 mL of CH2Cl2 and organic layer was washed with NaHCO3
and brine. The organic layers were combined and dried over anhydrous Na2SO4 and the
solvent was removed by rotovaporation as well as black oily crude product obtained.
1NMR

indicated that roughly 85% of the mixture contained Mthyl-7-benzoyl 5-chloro-2,3-

dihdrobenzo[b]furan-3- carboxylate (15). Next, the crude product was placed on the silica
plug and washed with hexane followed by washed with ethyl acetate /hexane (5: 95)
solvent. Nitrobenzene and unreacted starting material was remove. Mixture of product
and starting material was separated from the silica plug with CH2Cl2 followed by
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rotovaporation to remove CH2Cl2. After that, Hexane was added to the mixture and heated
to 700 C and cooled down to RT and crystal of pure product was started to form. This
crystallization process was repeated for several times and 102 mg (76% yield) of pure
solid Methyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15) was
obtained.
1H

NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t,

J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H),
3.86(s,3H).

3.2.1.7 Method D: Traditional synthesis of Methyl-7-benzoyl 5-chloro-2,3- dihydro
benzo [b] furan-3- carboxylate (15) using Bi(OTf)3 as a catalyst.

Methyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (3) (2.47g,10.44 mmol) was
added to a 250 mL 3-neck round bottom flask fitted with condenser and septum connected
to a nitrogen line. Then, Bi(OTf)3 (1.5g, 2.28 mmol) was added to the flask followed by
the addition of 30 mL of nitrobenzene. After that, benzoyl chloride (2.7 mL,23.24 mmol)
was added by a syringe. Then, the reaction mixture was heated to 900C with constant
stirring for 3 days. After that, the reaction mixture was cooled down to r.t. and transferred
to the Elamnary flask. The dark oil residue was quenched with 50 ml of H2O and 20 ml
CH2Cl2 was added to the flask. Then, the solution was passed through the silica plug and
the filtrate was extracted with 250 mL of CH2Cl2 and organic layer was washed with
NaHCO3 and brine. After this, the organic layers were combined and dried over
anhydrous Na2SO4 and the solvent was removed by rotovaporation as well as black oily
crude product obtained. 1NMR indicated that roughly 87% of the mixture contained Mthyl7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3- carboxylate (15). Then, the crude product
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was placed on the silica plug and washed with hexane followed by washed with ethyl
acetate /hexane (5: 95) solvent. Nitrobenzene and unreacted starting material was
remove. Mixture of product and starting material was separated from the silica plug with
CH2Cl2 followed by rotovaporation to remove CH2Cl2. After that, Hexane was added to
the mixture and heated to 700 C and cooled down to RT and crystal of pure product was
started to form. This crystallization process was repeated for several times and 2.32g
(70%

yield) of

pure

solid

Methyl-7-benzoyl 5-chloro-2,3-dihdrobenzo[b]furan-3-

carboxylate (15) was obtained.
1H

NMR (300 MHz, CDCl3): δ 7.83 (d,J= 5Hz,2H), 7.62(t,J=5Hz,1H), 7.55(S,1H,),7.49( t,

J=5Hz, 2H), 7.44(S, 1H), 4.99 (t,J=10Hz,1H),4.76(t,J=10Hz,1H),4.40(t,J=10Hz,1H),
3.86(s,3H).

3.2.1.8. Preparation of Methyl-7-benzoyl

5-Fluoro-2,3-dihdrobenzo[b]furan-3-

carboxylate (25): Method C was followed for the preparation of 25. A 10-mL pressurized
glass tube with High -pressure tolerance septum equipped with a magnet bar was
charged with Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (0.1g,0.51
mmol), Bi(OTf)3 (30mg mg,0.046 mmol) and Benzoyl chloride (0.08 mL, 0.1 mmol) in 1
mL of Nitrobenzene. Then, glass tube was placed into CEM microwave for 1 hr. to react
at 1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.12 mg,
78 % of yield) isolated as a solid after crystallization in hexane.
For Traditional synthesis of 25 Method D was followed. To a 250 mL 3-neck round
bottom flask fitted with condenser and septum connected to a nitrogen line was charged
with Methyl 5-Fluoro-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (2.86g,14.58 mmol),
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Bi(OTf)3 (1.8g,2.74 mmol), Benzoyl chloride (3.19 mL, 27.46 mmol) and 35 mL of
Nitrobenzene. Then, the reaction mixture was heated at 900 C with constant steering for
3-days. The title compound (2.19 g, 50% of yield), was isolated as a solid after
crystallization in hexane.
1H

NMR (300 MHz, CDCl3): δ 8.10( s,1H),7.80(s,1H),7.59(dd,J=6Hz,2H),7.10(t,J=3Hz,

1H),6.89(t,J=3Hz,1H),6.76(dd,J=9Hz,1H),4.96 (t,J=10Hz,1H),4.71(t,J=10Hz,1H), 4.35 (t,
J=10Hz,1H), 3.81(s,3H).
3.2.1.9. Preparation of Methyl-7-benzoyl 5-Methyl-2,3-dihdrobenzo[b]furan-3carboxylate (30): Method C was followed for the preparation of 30. A 10-mL pressurized
glass tube with High -pressure tolerance septum equipped with a magnet bar was
charged with Methyl 5-Methyl-2,3-dihdrobenzo[b]furan-3- carboxylate (29) (0.1g,0.50
mmol), Bi(OTf)3 (30mg mg,0.046 mmol) and Benzoyl chloride (0.08 mL, 0.10 mmol) in 2
mL of Nitrobenzene. Then, glass tube was placed into CEM microwave for 1 hour to react
at 1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.107g,
72 % of yield) isolated as a solid after crystallization in hexane.
For Traditional synthesis of 25 Method D was followed. To a 250 mL 3-neck round
bottom flask fitted with condenser and septum connected to a nitrogen line was charged
with Methyl 5-methyl-2,3-dihdrobenzo[b]furan-3- carboxylate (24) (1.2g,6.02 mmol),
Bi(OTf)3 (0.82g, 1.25 mmol), Benzoyl chloride (1.6 mL, 13.77 mmol) and 25 mL of
Nitrobenzene. After that, the reaction mixture was heated at 900 C with constant steering
for 3-days. The title compound (1.37 g, 77% of yield), isolated as a solid after
crystallization in hexane.
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1H

NMR(500 MHz, CDCl3):δ 7.81(d,2H),7.58(t,J=9Hz,1H),7.46(t,J=9Hz,2H),7.28(s,2H)

4.95(dd, J=9Hz,1H), 4.69(t, J=9Hz, 1H), 4.35(t, J=9Hz,1H), 3.82 (s,3H).

3.2.1.10. Preparation of Methyl-7-benzoyl 5-Methoxy-2,3-dihdrobenzo[b]furan-3carboxylate (36): Method C was followed for the preparation of 36. A 10-mL pressurized
glass tube with Teﬂon-coated septum equipped with a magnet bar was charged with
Methyl-5-methoxy-2,3-dihdrobenzo[b]furan-3-carboxylate (35) (0.1g,0.48 mmol), Bi(OTf)3
(30mg mg,0.046 mmol) and Benzoyl chloride (0.12 mL, 1.06 mmol) in 1.0 mL of
Nitrobenzene. Then, glass tube was placed into CEM microwave for 30 min to react at
1400 C, temperature, 40 PSI pressure with high steering. The title compound (0.075g, 50
% of yield) was isolated as a solid after crystallization in hexane.
For Traditional synthesis of 36 Method D was followed. To a 250 mL 3-neck round
bottom flask fitted with condenser and septum connected to a nitrogen line was charged
with Methyl-5-methoxy-2,3-dihdrobenzo[b]furan-3-carboxylate (35) (1.5g,7.2mmol),
Bi(OTf)3 (0.94g, 1.43 mmol), Benzoyl chloride (1.8 mL, 15.84 mmol) and 20 mL of
Nitrobenzene. Then, the reaction mixture was heated at 900 C with constant steering for
3-days. The title compound (1.46 g, 65% of yield), was isolated as a solid after
crystallization in hexane.
1H

NMR(500 MHz, CDCl3):δ 7.60(dd,J=2H),7.48 (t,J=9Hz,1H),7.45(t,J=9Hz,2H),

7.28(s,2H) 4.92(dd, J=9Hz,1H), 4.72(t, J=9Hz, 1H), 4.38(t, J=9Hz,1H), 3.82 (s,3H).
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3.2.1.11. Preparation of 7-(4-tri-fluromethyl) Benzoyl- 5-Chloro-2,3-dihydrobenzo
[b]furan-3- carboxylate (37):
Method C was followed for the preparation of 37. A 10-mL pressurized glass tube with
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092
mmol) and 7-(4-tri-fluromethyl) benzoyl chloride (0.3mL, 2.02 mmol) in 1.0 mL of
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 1200
C, temperature, 40 PSI pressure with high steering. The title compound (0.143g, 79 % of
yield) was isolated as a solid after crystallization in hexane.
1H

NMR (500 MHz, CDCl3): δ 8.02 (d,J=5Hz,1H),7.91(d,J=5Hz, 1H),7.80(dd, J=5hz,

1H), 7.59(s,1H) 7.48 (s,1H), 7.49(s,1H),7.34(d,J=5Hz,1H) 4.98(t,J=5Hz,1H),4.73(t,
J=5Hz,1H),4.40(t,J=5Hz,1H), 3.87(s,3H)
3.2.1.12. Preparation of 7-(4-fluro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3carboxylate (39):
Method C was followed for the preparation of 39. A 10-mL pressurized glass tube with
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092
mmol) and 7-(4-fluromethyl) benzoyl chloride (0.3mL, 5.06 mmol) in 1.0 mL of
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 120 0
C, temperature, 40 PSI pressure with high steering. The title compound (75mg, 48 % of
yield) was isolated as a solid after crystallization in hexane.
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1H

NMR(500 MHz, CDCl3):δ 7.78(d,J=10Hz,2H),7.62 (s,1H),7.45(t,J=10Hz,2H),

7.29(s,2H) 4.99(t,J=5Hz,1H), 4.76(t, J=5Hz, 1H), 4.44(t, J=5Hz,1H), 3.86 (s,3H)
3.2.1.13. Preparation of 7-(4-Chloro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan3- carboxylate (41):
Method C was followed for the preparation of 41. A 10-mL pressurized glass tube with
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092
mmol) and 7-(4-fluromethyl) benzoyl chloride (0.06mL, 0.47 mmol) in 0.5 mL of
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 120 0
C, temperature, 40 PSI pressure with high steering. The title compound (0.115g, 70 % of
yield) was isolated as a solid after crystallization in hexane.
1H

NMR(500 MHz, CDCl3):δ 7.77(d,J=9Hz,2H),7.55 (s,1H),7.74(t,J=9Hz,2H), 7.28(s,2H)

4.98(t,J=15Hz,1H), 4.77(t, J=15Hz, 1H), 4.41(t, J=15Hz,1H), 3.85 (s,3H)
3.2.1.14. Preparation of 7-(4-Nitro) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3carboxylate (43):
Method C was followed for the preparation of 43. A 10-mL pressurized glass tube with
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092
mmol) and 7-(4-nitro) benzoyl chloride (0.174g, 0.94 mmol) in 2 mL of Nitrobenzene.
Then, glass tube was placed into CEM microwave for 1hr to react at 1200 C, temperature,
40 PSI pressure with high steering. The title compound (86.70mg, 56 % of yield) was
isolated as a solid after crystallization in hexane.
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1H

NMR (300 MHz, CDCl3): δ 7.86 (s,1H),7.81(dd,J=15Hz,2H)7.40(s,1H), 6.81(d,2H),

4.93(t,J=6Hz),4.73(t, j=12Hz,1H),4.66(t,1H), 3.89(s,3H).

3.2.1.15. Preparation of 7-(4-Methyl thiol) Benzoyl- 5-Chloro-2,3-dihydrobenzo
[b]furan-3- carboxylate (45):
Method C was followed for the preparation of 45. A 10-mL pressurized glass tube with
High -pressure tolerance equipped with a magnet bar was charged with 5-chloro-2,3dihdrobenzo[b]furan-3- carboxylate (3) (100 mg.,0.47 mmol) Bi(OTf)3 (60mg mg,0.092
mmol) and 7-(4-Methyl thiol) benzoyl chloride (0.16ml, 1.03 mmol) in 2 mL of
Nitrobenzene. Then, glass tube was placed into CEM microwave for 1hr to react at 140 0
C, temperature, 40 PSI pressure with high steering. The title compound (92.02mg, 54 %
of yield) was isolated as a solid after crystallization in hexane.
1H

NMR (500MHz, CDCl3):δ 8.35 (s,2H),8.16(d,J=6Hz,2H),7.84(d,J=9Hz,2H), 7.51(dd,

J=9Hz, 7.44(t,J=2Hz, 1H),4.98(t, J=9Hz,1H), 4.76(t, J=9Hz, 1H),4.16(t,J=9Hz,1H), 3.82
(s,3H).
3.2.1.16. Preparation of 5-Chloro -7-Benzoyl -2,3-dihydrobenzo [b] furan-3carboxylic acid (5).
Methyl-7-Benzoyl- 5-chloro-2,3-dihydro benzo[b]furan-3-carboxylate (15) (1g, 3.15mmol)
was dissolved in 30mL methanol:H20(1:1) solution followed by addition of sodium
hydroxide (1.26g,31.5mmol). The reaction mixture was stirred for overnight at RT.

142

30 mL of deionized water was poured to the reaction mixture to quench the reaction and
the solution was extracted with ethyl acetate. The Erlenmeyer flask containing the
aqueous layer was placed in an ice bath and 5M HCl was added dropwise until P H would
be 1.0. The solution was extracted with ethyl acetate. The organic layers were combined,
washed with brine and dried over anhydrous Na2SO4 and the solvent was removed by
rotovaporation as well as pale yellow solid product obtained (0.94g, 99% yield).
1H

NMR (300 MHz, CDCl3): δ 7.84 (d,J= 5Hz,2H), 7.62(t,J=5Hz,2H), 7.51( t, J=5Hz,

2H), 7.47(S,1H,), 7.29(S, 1H), 4.95(t,J=10Hz,1H),4.78(t,J=10Hz,1H),4.46(t,J=10Hz,1H).
Analytical data was matched with the previous data33.
3.2.1.17.a. 5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (26), 5Methyl- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (31), 5-Methoxy 7Benzoyl --2,3-dihydrobenzo [b] furan-3- carboxylic acid (36), 7-(4-trifluromethyl) Benzoyl
-5-Chloro-2,3-dihydro benzo[b] furan-3- carboxylic acid (38), 7-(4-fluro) Benzoyl -5Chloro-2,3- dihydrobenzo[b] furan-3- carboxylic acid (41),7-(4-chloro) Benzoyl -5-Chloro2,3-

dihydrobenzo[b] furan-3-carboxylic acid (42),7-(4-Nitro) Benzoyl- 5-Chloro-2,3-

dihydrobenzo [b]furan -3-carboxylic acid (44) were prepared by following procedure in
3.2.1.16.
Analytical data:
5-Fluoro- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (26)
1H

NMR (300 MHz, CDCl3): δ 11.16 (s, 1H), 7.83(d,J=10Hz,2H), 7.61(t,J=10Hz,1H),

7.45(s,1H), 4.98(t,J=10Hz,1H),4.75(t,J=10Hz,1H),4.44(t,J=10Hz,1H).
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5-Methyl- 7-Benzoyl -2,3-dihydrobenzo [b] furan-3- carboxylic acid (31)
1H

NMR (300 MHz, CDCl3): δ 7.78(d,J=5Hz,2H), 7.62(t,J=5Hz,2H),7.51(t,J=15Hz ,3H),

4.86(t,J=10Hz,1H),4.65(t,J=5Hz,1H),4.39(t,J=5Hz,1H).
7-(4-fluro) Benzoyl -5-Chloro-2,3- dihydrobenzo[b] furan-3- carboxylic acid (41)
1H

NMR (500 MHz, CDCl3): δ 7.78(d,J=10Hz,2H), 7.62(s,J=10Hz,1H),7.49(d,J=10Hz

,2H), 4.99(t,J=5Hz,1H),4.76(t,J=5Hz,1H),4.44(t,J=5Hz,1H).
7-(4-chloro) Benzoyl -5-Chloro-2,3- dihydrobenzo[b] furan-3-carboxylic acid (42).
1H

NMR (500 MHz, CDCl3): δ 7.61(d,J=15Hz ,2H),7.56 (s,1H) ,7.45(t,J=10Hz,2H),7.29

(s,1H),4.96(t,J=10Hz,1H),4.73(t,J=10Hz,1H),4.40(t,J=10Hz,1H).
7-(4-trifluromethyl) Benzoyl- 5-Chloro-2,3-dihydrobenzo [b]furan-3- carboxylic acid (38)
1H

NMR (500 MHz, CDCl3): δ 7.78 (d,J=10Hz,1H),7.62(s,1H) 7.48 (s,1H), 7.29(s,1H),

4.99(t,J=5Hz,1H),4.76(t, J=12Hz,1H),4.45(t,J=10Hz,1H).
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4. Biological Evaluations.
4.1. COX Inhibition Screening Assay at Vanderbilt University, Nashville, Tennessee.
Concentration-dependent inhibition reactions were completed by pre-incubating the
inhibitor and enzyme for 17 min at 250C, followed by 3 min at 370C prior to the addition of
50 µM [1-14C]-AA (~55 mCi/mmol, Perkin Elmer, Waltham, MA) for 30 sec. at 370C.
Reactions were terminated, and the resulting mixtures were analyzed for substrate
consumption by thin-layer chromatography as previously described194. Inhibitor
concentrations required for 50% inhibition of enzyme activity (IC50) were determined
graphically using Prism (GraphPad Software, La Jolla, CA) and were the average of at
least two independent determinations.
4.2. Time-Dependent COX Inhibition Assays at Vanderbilt University, Nashville,
Tennessee.
Time-dependent inhibition assays were conducted by pre-incubating increasing
concentrations of the inhibitor with m/hCOX-2, oCOX-1, or the active site mCOX-2
mutants for various time points (0, 0.125, 0.25, 0.5, 1, 3, 5, 15, 30 and 60 min) at 370C
prior to the addition of 50 µM [1-14C]-AA for 30 sec. at 370C. Reactions were terminated
and analyzed by thin layer chromatography as described above. The values were the
average of at least three independent determinations.
4.3. COX Inhibition Screening Assay by Cayman Chemical, MI.

All reactions were performed in 100 mM Tris (pH 8.0), 5 mM EDTA, 2 mM phenol, and 1
μM heme. Compounds were diluted in DMSO and incubated with enzyme for 10 minutes
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at 370C, followed by the initiation of the reaction with 100 μM arachadonic acid. Reactions
proceed at 370C for 2 minutes, then quenched with 120 mM HCl containing 29 mM
stannous chloride. SnCl2reduced PGH2 was measured using Cayman Chemical’s
Prostaglandin Screening ELISA Kit (Item No 514012). The amount of prostaglandin
product produced from each reaction was calculated using non-linear regression (fourparameter fit) using Graph Pad Prism V.6.07. Percent inhibition for each compound was
calculated using the vehicle and inhibited control compound wells. From the studies it is
found that BRL-37959 and it’s the analogs do not bind with COX-2 enzymes.

4.4. Anti-proliferative assay
The cytotoxicity of the BRL-37959 against the COLO-205 (colon cancer, ATCC), MDAMB-231 (breast cancer, ATCC), SKOU-3(ovarian cancer, ATCC), and DU-145 (prostate
cancer, ATCC), cell lines was tested using the MTT assay as previously described.221, 222
Concisely, the tumor cells (1x104cells/well) were seeded in 96-well microtiter plates and
incubated for 24 h at 37ºC. Following incubation, the media was replaced with fresh media
containing the above compound at concentrations ranging from 1 µM to 1 pM diluted in
DMSO and incubated for an additional 48 h. Drug was run in duplicate or triplicate and
control cells received fresh media with DMSO concentration equivalent to the treatment
groups. Then, the wells were washed twice with warm PBS and incubated for another 4
h with RPMI 1640 media containing 250 µg/mL of MTT. Later, aspirating the culture
medium, 200 µL of DMSO was added to dissolve the precipitate and the resulting solution
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was measured for absorbance at 570 nm with a reference wavelength of 690 nm using a
microplate reader 56 (Infinite M200 Pro TECAN). Results were used to find out the growth
inhibition- 50% (GI50) of the compound.
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